<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Transl Med</journal-id><journal-id journal-id-type="iso-abbrev">J Transl Med</journal-id><journal-title-group><journal-title>Journal of Translational Medicine</journal-title></journal-title-group><issn pub-type="epub">1479-5876</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7215129</article-id><article-id pub-id-type="publisher-id">2363</article-id><article-id pub-id-type="doi">10.1186/s12967-020-02363-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Allo-priming as a universal anti-viral vaccine: protecting elderly from current COVID-19 and any future unknown viral outbreak</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9342-9337</contrib-id><name><surname>Har-Noy</surname><given-names>Michael</given-names></name><address><email>harnoy@immunovative.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Or</surname><given-names>Reuven</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.17788.31</institution-id><institution-id institution-id-type="ISNI">0000 0001 2221 2926</institution-id><institution>Cancer Immunotherapy and Immunobiology Center, </institution><institution>Hadassah-Hebrew University Medical Center, </institution></institution-wrap>9112001 Jerusalem, Israel </aff><aff id="Aff2"><label>2</label>Immunovative Therapies, Ltd, Malcha Technology Park, B1/F1, 9695101 Jerusalem, Israel </aff><aff id="Aff3"><label>3</label>Mirror Biologics, Inc., 4824 E Baseline Rd #113, Phoenix, AZ USA </aff></contrib-group><pub-date pub-type="epub"><day>12</day><month>5</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>12</day><month>5</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>18</volume><elocation-id>196</elocation-id><history><date date-type="received"><day>21</day><month>4</month><year>2020</year></date><date date-type="accepted"><day>4</day><month>5</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">We present the rationale for a novel allo-priming approach to serve the elderly as a universal anti-virus vaccine, as well serving to remodel the aging immune system in order to reverse immunosenescence and inflammaging. This approach has the potential to protect the most vulnerable from disease and provide society an incalculable economic benefit. Allo-priming healthy elderly adults is proposed to provide universal protection from progression of any type of viral infection, including protection against progression of the current outbreak of COVID-19 infection, and any future variants of the causative SARS-CoV-2 virus or the next &#x02018;Disease X&#x02019;. Allo-priming is an alternative approach for the COVID-19 pandemic that provides a back-up in case vaccination strategies to elicit neutralizing antibody protection fails or fails to protect the vulnerable elderly population. The allo-priming is performed using activated, intentionally mismatched, ex vivo differentiated and expanded living Th1-like cells (AlloStim<sup>&#x000ae;</sup>) derived from healthy donors currently in clinical use as an experimental cancer&#x000a0;vaccine. Multiple intradermal injections of AlloStim<sup>&#x000ae;</sup> creates a dominate titer of allo-specific Th1/CTL memory cells in circulation, replacing the dominance of exhausted memory cells of the aged immune system. Upon viral encounter, by-stander activation of the allo-specific memory cells causes an immediate release of IFN-&#x003d2;, leading to development of an &#x0201c;anti-viral state&#x0201d;, by-stander activation of innate cellular effector cells and activation of cross-reactive allo-specific CTL. In this manner, the non-specific activation of allo-specific Th1/CTL initiates a cascade of spatial and temporal immune events which act to limit the early viral titer. The release of endogenous heat shock proteins (HSP) and DAMP from lysed viral-infected cells, in the context of IFN-&#x003d2;, creates of conditions for in situ vaccination leading to viral-specific Th1/CTL immunity. These viral-specific Th1/CTL provide sterilizing immunity and memory for protection from disease recurrence, while increasing the pool of Th1/CTL in circulation capable of responding to the next viral encounter.</p></sec><sec><title>Conclusion</title><p id="Par2">Allo-priming has potential to provide universal protection from viral disease and is a strategy to reverse immunosenescence and counter-regulate chronic inflammation (inflammaging). Allo-priming can be used as an adjuvant for anti-viral vaccines and as a counter-measure for unknown biological threats and bio-economic terrorism.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>COVID-19</kwd><kwd>Immunosenescence</kwd><kwd>Inflammaging</kwd><kwd>Cell therapy</kwd><kwd>Immunotherapy</kwd><kwd>Vaccine</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par32">Herein we propose to use a novel allo-priming strategy using patented, allogeneic Th1-like immune cells conjugated to CD3/CD28 microbeads (AlloStim<sup>&#x000ae;</sup>) to serve as a &#x0201c;Universal Anti-Viral Vaccine&#x0201d; to protect the health of elderly adults. Vaccination has been a strategy to protect against viral diseases in adults, such as influenza, pneumococcal pneumonia, shingles and hepatitis A/B. Successful prophylactic vaccination mechanisms provide protection through eliciting neutralizing antibodies to prevent viral entry into cells. However, this strategy does not provide&#x000a0;protection against antigenic shift or drift variants of the original virus [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Currently, there are at least three known variants of the SARS-CoV-2 virus [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par33">In addition, pathological viruses are intracellular and not always accessible to antibodies. For this reason, neutralizing antibody vaccines have not been effective against a number of complex viruses, including HIV, HCV, CMV, Zika, RSV,&#x000a0;Dengue and SARS/MERS. For the same reason, convalescent serum prophylaxis and treatment may not be able to confer sterilizing immunity or memory. These sophisticated viruses may&#x000a0;require an effective cellular immune response for sterilizing immunity [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>]. Without sterilizing cellular immunity, there can be viral recurrence as has been reported with COVID-19 [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par34">Many efforts are underway to develop anti-viral vaccines which elicit protective cellular immunity [<xref ref-type="bibr" rid="CR10">10</xref>], but these have not yet been successfully translated to demonstrate clinical benefit [<xref ref-type="bibr" rid="CR11">11</xref>]. The age-related functional decline in cellular immunity (immunosenescence) makes the elderly less able to mount a cellular immune response to vaccination, making this population more vulnerable to morbidity and mortality associated with viral diseases and less likely to respond to an anti-viral vaccine.</p><p id="Par35">In addition, elderly also suffer detrimental effects on their immune function due to chronic inflammation, known as &#x0201c;inflammaging&#x0201d; [<xref ref-type="bibr" rid="CR12">12</xref>]. Inflammaging is correlated with comorbidities such as cancer, arthrosclerosis, neurodegenerative diseases (e.g., Alzheimer&#x02019;s and Parkinson&#x02019;s disease) all which increase the likelihood of serious progression of viral infection. In addition, the aging of the structure and function of the lungs contributes to increased incidence of pneumonia, acute respiratory distress syndrome (ARDS) and sepsis in the elderly after respiratory viral infection.</p><p id="Par36">The remodeling of the senescent immune systems of the elderly through allo-priming is proposed as a method to restore cellular immune function in this population. The ability to restore functional cellular immunity to the elderly can increase responsiveness to viral infections, including COVID-19 and any future emergent novel virus. In essence, an elderly immune system modulated by allo-priming would potentially respond to viral infection in a similar manner to the immune response of younger individuals, resulting in less serious disease. The immunomodulation of the elderly immune system to function more like a youthful immune system should also restore responsiveness to any current or future viral-specific vaccines. A more&#x000a0;balanced immune system&#x000a0;in the elderly can&#x000a0;also counter-regulate inflammaging, providing broad ranging health benefits to the elderly and to society [<xref ref-type="bibr" rid="CR13">13</xref>].</p></sec><sec id="Sec2"><title>Main text</title><sec id="Sec3"><title>Allopriming</title><p id="Par37">The allo-priming concept is designed to prime the immune systems of healthy elderly adults to create high titers of allo-specific Th1/CTL memory cells which can become activated upon encounter with any virus (by-stander activation) [<xref ref-type="bibr" rid="CR14">14</xref>]. The by-stander activation of allo-specific Th1/CTL memory cells upon viral encounter causes the release of interferon-gamma (IFN-&#x003d2;), which creates an &#x0201c;anti-viral state&#x0201d; [<xref ref-type="bibr" rid="CR15">15</xref>]. IFNs create an antiviral state in both virus-infected cells and uninfected, bystander cells, by inducing a program of gene transcription that interferes with multiple stages of viral replication cycles through various mechanisms [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par38">The IFN-&#x003d2; release from by-stander activated allo-specific Th1/CTL memory cells activates innate effector cells (e.g., NK, NKT and macrophages) which in turn release additional IFN-&#x003d2;, sustaining the anti-viral state. These activated innate effector cells lyse viral infected cells, controlling&#x000a0;acute viral burden. By-stander activation of resident allo-specific CTL can also cross-react to lyse viral infected cells [<xref ref-type="bibr" rid="CR17">17</xref>]. The lysis of viral infected cells by activated innate effector cells and cross-reactive allo-specific memory CTL releases &#x0201c;danger signals&#x0201d; [<xref ref-type="bibr" rid="CR18">18</xref>] and heat shock proteins (HSP) [<xref ref-type="bibr" rid="CR19">19</xref>] which chaperone viral antigens (e.g., GRP78, HSP70) [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>] into the microenvironment, creating the conditions for &#x0201c;in situ vaccination&#x0201d;, which leads to development of viral-specific cellular immunity.</p><p id="Par39">Antigen presenting cells (APC), such as dendritic cells (DC), engulf and process released HSP-chaperoned viral antigens. Processing in the context of danger signals and IFN-&#x003d2;, causes the maturation of immature DC to IL-12+ DC [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. IL-12 production acts to further increases IFN-&#x003d2;, sustaining the anti-viral state and upregulating MHCI, MHCII and co-stimulatory molecules on APC [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. The mature DC migrate to regional lymph nodes and display viral antigens on MHC I and MHC II with co-stimulator CD80/86 expression, leading to viral-specific Th1/CTL expansion. The IFN-&#x003d2; upregulates MHCI on viral infected cells so these cells&#x000a0;can be recognized and killed&#x000a0;by viral-specific CTL [<xref ref-type="bibr" rid="CR26">26</xref>]. These viral-specific CTL can&#x000a0;then orchestrate a sterilizing immune response and later differentiate into memory cells that provides protection from re-infection.</p><p id="Par40">Thus, allo-antigenic priming can modulate the systemic immune balance and provide a pool of non-exhausted allo-specific Th1/CTL&#x000a0;memory cells capable of rapidly responding to viral infection. The non-specific activation of these allo-specific memory cells upon viral encounter causes release of IFN-&#x003d2;. The release of IFN-&#x003d2; orchestrates the sequential activation of immune cells resulting in formation of an antiviral state, innate&#x000a0;elimination of invading viruses and development of a&#x000a0;viral-specific effector response and&#x000a0;memory.</p><p id="Par41">Each time this cascade is initiated by viral encounter, the virus elimination serves as a booster to the original allo-antigenic priming. The new viral-specific Th1/CTL memory cells resulting from viral elimination join the resident memory&#x000a0;allo-specific Th1/CTL resulting from the allo-antigenic priming, increasing the titer of Th1/CTL memory cells in circulation. Encounter with each new virus will non-specifically activate all previous non-exhausted&#x000a0;memory cells and support&#x000a0;the immune cascade that eliminates the new virus. Memory Th1/CTL to each new virus, in turn, increases the titer of Th1/CTL memory cells primed to respond to a subsequent viral encounter.</p><p id="Par42">Creating a memory Th1/CTL immune response to alloantigen thus provides protection against an unrelated viral infection through the immune mechanism known as &#x0201c;heterologous immunity&#x0201d;. Heterologous immunity occurs when by-stander activation of immune memory cells to one virus alters the immune response to, and the course of infection of, an unrelated virus encountered later [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>].</p><p id="Par43">In this manner, healthy adults can be provided pan-viral&#x000a0;protection against viral&#x000a0;infections, including SARS-CoV-2, influenza&#x000a0;A/B and any future variants and&#x000a0;unknown novel viruses that may emerge. This self-amplifying process can provide long-term disease mitigation and universal&#x000a0;protection against known and unknown viral infections&#x000a0;for the elderly.</p></sec><sec id="Sec4"><title>Immunity to alloantigens</title><p id="Par44">In order to effectuate the anti-viral and anti-aging immune&#x000a0;mechanisms, the allo-priming must elicit allo-specific Th1/CTL immunity. Injection of alloantigen alone can elicit humoral&#x000a0;and Th2 responses, and multiple injections can result in tolerance to the allo-antigens. Many factors, both intrinsic and extrinsic to the allograft, can influence the nature and magnitude of the allo-rejection immune response, including the nature of the allograft, the site of the body where it is placed, and the immunological status of the recipient [<xref ref-type="bibr" rid="CR29">29</xref>].</p><p id="Par45">To assure consistent differentiation of allo-specific Th1/CTL memory after allo-antigen priming, regardless of host immune status and age, a bioengineered, patented, immune cell called &#x0201c;AlloStim<sup>&#x000ae;&#x0201d;</sup> is used. AlloStim<sup>&#x000ae;</sup> is living, activated, intentionally mismatched, ex vivo expanded and differentiated allogeneic Th1-like cells derived from healthy donors. Injection of undifferentiated allogeneic immune cells or non-activated allogeneic immune cells were not able to elicit allo-specific Th1 memory, while priming with activated allogeneic Th1-like AlloStim<sup>&#x000ae;</sup> cells elicited dominant Th1 immunity and&#x000a0;had both a protective effect and a therapeutic effect in a cancer model [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>].</p><p id="Par46">AlloStim<sup>&#x000ae;</sup> cells are administered intradermally (ID) in an activated state. To assure the injected cells are activated when administered, they are prepared with anti-CD3/anti-CD28-coated microbeads attached. The activated AlloStim<sup>&#x000ae;</sup> cells are formulated as a frozen dosage form at 1&#x02009;&#x000d7;&#x02009;10<sup>7</sup>&#x000a0;cells/ml in PlasmaLyte A containing 1% human serum albumin and 2% DSMO. Individual doses of 0.5&#x000a0;ml are thawed and administered intradermally every 3&#x02013;4&#x000a0;days for up to five total doses. This priming schedule is sufficient to provide high titers of circulating allo-specific Th1/CTL. AlloStim<sup>&#x000ae;</sup>&#x000a0;has been evaluated in Phase I/II, Phase II and Phase IIA clinical trials in USA and Thailand in chemotherapy-refractory metastatic solid tumor patients. Phase IIB pre-registration and Phase IIB/III randomized, controlled registration clinical trials are currently being prepared for launch in third line metastatic colorectal cancer and advanced/metastatic hepatocellular carcinoma in USA and Asia, respectively. In these human clinical trials, AlloStim<sup>&#x000ae;</sup> has demonstrated ability to down-regulate checkpoint molecules in the tumor microenvironment, cause system-wide infiltration of effector T-cells and NK cells into metastatic lesions (conversion from &#x0201c;cold&#x0201d; to &#x0201c;hot&#x0201d;)&#x000a0;and has consistently demonstrated a tail of between 20 and 35% of long-term survivors in chemotherapy-refractory metastatic&#x000a0;disease&#x000a0;with a good safety profile [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>].</p><p id="Par47">Activated AlloStim<sup>&#x000ae;</sup> express high density CD40L and type 1 cytokines, including IFN-&#x003d2;, TNF-&#x003b1; and GM-CSF. AlloStim<sup>&#x000ae;</sup> has been shown to modulate the immune systems of heavily pre-treated metastatic cancer patients (which resemble the senescent immune systems of the elderly) and has been&#x000a0;used in protocols which were designed to elicit the same anti-tumor mechanism of allogeneic stem cell transplant procedures (graft vs tumor or &#x0201c;GVT&#x0201d;) without the need for a matched donor, chemotherapy conditioning or risk of GVHD [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR34">34</xref>&#x02013;<xref ref-type="bibr" rid="CR38">38</xref>].</p><p id="Par48">Allogenic cells are highly immunogenic and are rejected even by immunocompromised hosts [<xref ref-type="bibr" rid="CR39">39</xref>]. The rejection of the mis-matched cells eliminates risk of GVHD side-effects of allogeneic cell administration. Multiple ID injections of AlloStim<sup>&#x000ae;</sup> amplify the titer of allo-specific Th1/CTL cells in circulation and a portion of these cells differentiate into long lasting memory cells. These allo-specific Th1/CTL memory cells provide a functional pool of immune cells that are capable of non-specific (by-stander) activation [<xref ref-type="bibr" rid="CR40">40</xref>] upon encounter with virus [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR41">41</xref>] resulting in immediate release of IFN-&#x003d2;.</p><p id="Par49">The production of proinflammatory cytokines by AlloStim<sup>&#x000ae;</sup>, including IFN-&#x003b3; and TNF-&#x003b1;, initially activates host NK cells to reject the allogeneic cells, due to missing self-MHC I on the CD4+ AlloStim<sup>&#x000ae;</sup> cells. The NK cell compartment is highly stable in terms of function and phenotype in the elderly [<xref ref-type="bibr" rid="CR42">42</xref>] and can therefore readily reject mismatched allogeneic cells. In subsequent ID AlloStim<sup>&#x000ae;</sup> injections, the production of IFN-&#x003d2; and expression of CD40L by AlloStim<sup>&#x000ae;</sup> activates macrophages that&#x000a0;reject the AlloStim<sup>&#x000ae;</sup> [<xref ref-type="bibr" rid="CR43">43</xref>]. The rejection of the allogeneic cells by NK cells or macrophages in the skin results in release of endogenous HSP and DAMP danger signals [<xref ref-type="bibr" rid="CR22">22</xref>], which in the context of CD40L and IFN-&#x003d2; expressed by AlloStim<sup>&#x000ae;</sup>&#x000a0;result in DC maturation to IL-12+ DC1 phenotype&#x000a0;and their migration to draining lymph nodes to interact with cognate T-cells to&#x000a0;elicit allo-specific Th1/CTL immunity [<xref ref-type="bibr" rid="CR44">44</xref>].</p></sec><sec id="Sec5"><title>Elderly adults</title><p id="Par50">The current COVID-19 viral pandemic has led to high number of deaths worldwide. This is the third serious coronavirus (CoV) outbreak in less than 20&#x000a0;years, following SARS in 2002&#x02013;2003 and MERS in 2012. Elderly people account disproportionately to the morbidity and mortality associated with CoV infection. Vaccines have been the main global strategy to minimize the impact of viral infections, but no successful vaccines have yet been developed for these previous highly virulent CoVs. In any event, elderly adults generally respond poorly to anti-viral vaccines [<xref ref-type="bibr" rid="CR45">45</xref>&#x02013;<xref ref-type="bibr" rid="CR47">47</xref>]. This creates a high unmet medical need for a vaccine to provide protection to the elderly from the current COVID-19 pandemic and protect from any future pandemics.</p><p id="Par51">While healthy younger adults generally present with more mild symptoms in response to viral infection, the elderly are slow to respond and are susceptible to higher viral titers and chronic viral infection which leads to progression to severe symptoms, especially in the setting of respiratory viral infections [<xref ref-type="bibr" rid="CR48">48</xref>&#x02013;<xref ref-type="bibr" rid="CR54">54</xref>]. The delayed and poorly effective responsiveness of elderly to viral infection is due, in large part, to compromised cellular immunity [<xref ref-type="bibr" rid="CR55">55</xref>&#x02013;<xref ref-type="bibr" rid="CR57">57</xref>] related to &#x0201c;immunosenescence&#x0201d; [<xref ref-type="bibr" rid="CR58">58</xref>&#x02013;<xref ref-type="bibr" rid="CR60">60</xref>].</p><p id="Par52">Elderly individuals have a significantly delayed innate immune response to viral infection and the adaptive immune response that follows is often sub-optimal [<xref ref-type="bibr" rid="CR61">61</xref>]. The delayed innate immune response results in accumulation of high viral titers which, in turn, serves to elicit a late over-active immune response which is&#x000a0;correlated with a more severe and often lethal clinical course [<xref ref-type="bibr" rid="CR62">62</xref>]. The acute high viral levels that are achieved in elderly as a result of late innate immune response also increases the virulence of the virus, by increasing chances of human-to-human spread of infection.</p><p id="Par53">There is a dysregulation in the Th1/Th2-system in the elderly, which is dominated by Th2-functions [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. Memory Th1/CTL cells in elderly adults are diminished and functionally exhausted [<xref ref-type="bibr" rid="CR65">65</xref>&#x02013;<xref ref-type="bibr" rid="CR68">68</xref>]. Memory cells of the elderly become exhausted due to lifelong antigenic challenge which can be&#x000a0;as a result of chronic viral infection (e.g., CMV, EBV, HBV, HCV) [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. Exhausted memory cells are unable to be non-specifically activated upon viral encounter. This defect in cellular immunity in the elderly&#x000a0;limits the availability of heterologous immune mechanisms to react to acute viral infection, which contributes to a&#x000a0;slower and often inadequate innate response to viral infection.</p><p id="Par54">Elderly also have limited T-cell repertoires [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR72">72</xref>] which inhibits their ability to develop viral-specific adaptive T-cell&#x000a0;immune responses, both prophylactically (by vaccination) [<xref ref-type="bibr" rid="CR73">73</xref>], and in situ (as a result of adaptive immune clearance of infection). This suppressed cellular immunity together with the aging of the respiratory organs makes elderly more susceptible to pathological effects of viral infection, especially effects of respiratory viral infection [<xref ref-type="bibr" rid="CR74">74</xref>]. The immune defects of the elderly make this population less likely to benefit from vaccinations as preventative measures against infectious diseases [<xref ref-type="bibr" rid="CR75">75</xref>].</p><p id="Par55">The current inability to provide elderly with protection from viral infection has an enormous economic impact on society [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR77">77</xref>]. The medical and economic impact of pandemics which disproportionately affect the elderly will be exacerbated as the proportion of the adult population increases globally. The current projections indicate that by 2050, the group of 60&#x000a0;years and older will represent 21.1% of the population [<xref ref-type="bibr" rid="CR78">78</xref>]. Therefore, there is an urgent unmet need to develop strategies to reverse immunosenescence and to develop methods which provide protection of the elderly population from viral epidemics.</p></sec><sec id="Sec6"><title>Immunomodulatation of the elderly immune system</title><p id="Par56">The progressive age-related dysregulation and decline of the immune system is known as &#x0201c;immunosenescence&#x0201d;. In the aging immune system, there is an accumulation of memory cells as a result of chronic stimulation with repeated clinical and subclinical infections [<xref ref-type="bibr" rid="CR13">13</xref>]. This chronic stimulation causes these memory cells to become exhausted and no longer able to function, contributing to an increased susceptibility of elderly to infectious pathogens [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR80">80</xref>]. The aging immune system is also characterized by a decline in the numbers of naive T cells, an imbalance in Th1/Th2 cell subsets, and a decrease in T cell receptor (TCR) repertoire [<xref ref-type="bibr" rid="CR75">75</xref>, <xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>].</p><p id="Par57">A cellular immune response with release of Th1 (type 1) cytokine profile, including IFN-&#x003d2;, TNF-&#x003b1; and IL-2, is known to be protective against most viral infections [<xref ref-type="bibr" rid="CR83">83</xref>]. IFN-&#x003d2; in particular has been shown to play an essential role in clearance of viral infection [<xref ref-type="bibr" rid="CR84">84</xref>]. Modulating the immune system of elderly individuals through alloantigen priming to provide high titers of non-exhausted Th1/CTL memory cells that can be non-specifically activated upon encounter with any virus to cause&#x000a0;release type 1 cytokines may provide an immediate anti-viral immune response upon viral exposure and&#x000a0;could also reinstate responsiveness to viral vaccines [<xref ref-type="bibr" rid="CR85">85</xref>]. The delay in IFN responses to virus infection in the elderly is due to active suppression by viral proteins and immunosenescence [<xref ref-type="bibr" rid="CR86">86</xref>], which allows virus to reach high titers early in infection, leading to immunopathology, T-cell apoptosis and progression to lethal pneumonia [<xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR88">88</xref>].</p><p id="Par58">The immediate release of IFN-&#x003d2; upon acute viral infection corrects the problem of delayed immune responsiveness and creates an early &#x0201c;anti-viral state&#x0201d; [<xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR90">90</xref>]. Establishment of the anti-viral state with early release of IFN-&#x003d2; provides a crucial initial line of defense against viral infection [<xref ref-type="bibr" rid="CR91">91</xref>]. The anti-viral state is normally induced through early release of type I/III IFN from viral infected cells [<xref ref-type="bibr" rid="CR92">92</xref>]. However, many viruses, including coronavirus, can suppress production of type I/III IFN as an immune avoidance mechanism [<xref ref-type="bibr" rid="CR93">93</xref>&#x02013;<xref ref-type="bibr" rid="CR96">96</xref>]. The strategy of providing a pool of non-exhausted memory cells which produce Type II IFN (IFN-&#x003d2;) upon viral encounter, overcomes the viral escape. IFN-&#x003d2; creates an anti-viral state even in type I/III IFN resistant cells [<xref ref-type="bibr" rid="CR97">97</xref>]. Further, IFN-&#x003d2; mobilizes innate effector cells that can respond rapidly to eliminate viral infection [<xref ref-type="bibr" rid="CR98">98</xref>] and also produce IFN-&#x003d2;. Thus, early IFN-&#x003d2; response to viral infection through allo-priming provides a rapid means of control over viral infection in the elderly.</p><p id="Par59">Chronic inflammation in the elderly is known to be associated with increased susceptibility to cancer [<xref ref-type="bibr" rid="CR99">99</xref>, <xref ref-type="bibr" rid="CR100">100</xref>], atherosclerosis [<xref ref-type="bibr" rid="CR101">101</xref>] and neurodegenerative disorders [<xref ref-type="bibr" rid="CR102">102</xref>, <xref ref-type="bibr" rid="CR103">103</xref>]. The modulation of the elderly immune system that occurs by allo-priming can also have the effect of counter-regulating resident chronic inflammation [<xref ref-type="bibr" rid="CR104">104</xref>, <xref ref-type="bibr" rid="CR105">105</xref>] which causes &#x0201c;inflammaging&#x0201d; resulting in reversing of immunosenescence [<xref ref-type="bibr" rid="CR106">106</xref>]. Thus, allo-priming protocols may not only provide universal anti-viral protection for the elderly, but may also serve as an &#x0201c;anti-aging&#x0201d; mechanism to protect from co-morbid diseases of aging.</p></sec><sec id="Sec7"><title>Clinical features of viral infection in elderly</title><p id="Par60">Allo-priming is predicted to reduce the severity of clinical symptoms upon encounter with virus. Clinical features of respiratory viral infections in humans vary from a first subset that experience mild flu-like symptoms which subside over a few days; to a second subset that experience moderate to severe flu-like symptoms associated with high fever, hypoxemia and progression to pneumonia-like symptoms. These symptomatic patients are at high risk to progress to acute respiratory distress syndrome (ARDS), sepsis, multiple organ failure and death. The subset with mild flu-like symptoms is associated with younger healthy individuals, while the subset associated with more severe symptoms is mostly associated with elderly adults that are frail and/or present with co-morbidities.</p><p id="Par61">The progression to more serious symptoms can occur even when there is a decline in virus titers [<xref ref-type="bibr" rid="CR107">107</xref>] connected to a late over-exuberant immune response. The initial delayed immune response leads to high viral titers which is followed by an exaggerated late immune response and a &#x0201c;cytokine storm&#x0201d;. This sequence of events is believed to be responsible for the severe symptoms related to respiratory virus infections in the elderly.</p><p id="Par62">During pathogenic virus infection, a cytokine storm leads to excessive inflammatory infiltrates and virus-induced tissue destruction which contributes to morbidity and mortality. The timing and source of the IFN in the cytokine storm can affect the clinical course of viral disease. High serum levels of IFN-&#x003d2; late in the course of viral infection is correlated with more severe disease [<xref ref-type="bibr" rid="CR108">108</xref>] and immunopathology [<xref ref-type="bibr" rid="CR109">109</xref>], whereas early IFN release results in lower viral titers and less severe disease. These observations support the prediction that early activation and release of IFN-&#x003d2; from non-exhausted allo-specific memory Th1/CTL will correct this problem and avoid progression to severe disease.</p><p id="Par63">The type of cytokine storm associated with severe disease is caused by cytokines released by activated monocytes, producing a storm of IFN-&#x003b1;, CCL-2, IL-6, TNF-&#x003b1;, CCL-3, CCL-5, CxCL-2, IL-1&#x003b1;, and IFN-&#x003b3;. This monokine cytokine storm is directly correlated with morbidity and mortality [<xref ref-type="bibr" rid="CR110">110</xref>]. The majority of fatalities associated with cytokine storm also developed bacterial pneumonia and sepsis. It is recognized that a major cause of respiratory failure is coexistent bacterial pneumonia leading to ARDS. ARDS is characterized by damage to the endothelial&#x02013;epithelial barrier of the alveoli, resulting in fluid leakage and accumulation in the alveolar lumen inhibiting gas exchange.</p><p id="Par64">The elderly have a pre-disposition to develop progressive respiratory compromise and sepsis. In fact, sepsis is considered a disease of aging [<xref ref-type="bibr" rid="CR111">111</xref>] and is among the top causes of ICU admissions of the elderly. The features of sepsis-induced immunosuppression, independent of age, share many of the same characteristics of immunosenescence. During the&#x000a0;last decades, there has been a&#x000a0;significant increase in incidence of sepsis in patients over 65&#x000a0;years of age [<xref ref-type="bibr" rid="CR112">112</xref>]. Many respiratory virus patients that progress to develop pneumonia and ARDS [<xref ref-type="bibr" rid="CR113">113</xref>, <xref ref-type="bibr" rid="CR114">114</xref>] later die due to sepsis.</p><p id="Par65">The overactive immune response to sepsis, including monokine &#x0201c;cytokine storm&#x0201d; results from over activated M1 macrophages in response to tissue damage [<xref ref-type="bibr" rid="CR115">115</xref>]. The response to sepsis is similar between old and younger patients. However, the mortality is much higher in older patients [<xref ref-type="bibr" rid="CR116">116</xref>]. The difference is related to the dysregulated immune systems of the elderly. The elderly are unable to turn down the over-activated monocyte response, leading to disease progression, while regulatory mechanisms in the young counter-act and prevent the consequences of monocyte over-activation.</p><p id="Par66">The dysregulated immune system of the elderly is related to the increased activity of myeloid-derived suppressor cells (MDSC) [<xref ref-type="bibr" rid="CR117">117</xref>, <xref ref-type="bibr" rid="CR118">118</xref>]. MDSCs are potent inducers of immunosenescence [<xref ref-type="bibr" rid="CR119">119</xref>], sepsis-acquired immunodeficiency [<xref ref-type="bibr" rid="CR120">120</xref>] as well as cancer metastasis and progression [<xref ref-type="bibr" rid="CR121">121</xref>]. MDSC are positively correlated with IL-6 and negatively correlated with IFN-&#x003d2; [<xref ref-type="bibr" rid="CR122">122</xref>, <xref ref-type="bibr" rid="CR123">123</xref>].</p><p id="Par67">Immunosenescence causes an imbalanced homeostatic regulation of innate and adaptive immune responses, diminishing the host capacity to rapidly restore balanced immune functions. Thus, combined effects of age-induced immunosuppression, delayed innate immune responses [<xref ref-type="bibr" rid="CR86">86</xref>], exaggerated late immune responses due to altered homeostasis [<xref ref-type="bibr" rid="CR88">88</xref>], all combine to make the post-viral infection period in the elderly have a longer duration. As a result, there are increased levels of viral propagation, higher incidences of tissue injury, and increased progression to ARDS and septic shock&#x000a0;in the elderly.</p><p id="Par68">Accordingly, allo-priming enabling the early release of IFN-&#x003d2; in response to viral infection can prevent the differentiation of MDSC and counter-regulate resident MDSC immunosuppression in the elderly [<xref ref-type="bibr" rid="CR124">124</xref>]. This will have the effect of remodeling the elderly immune system in a manner which will prevent the severe symptoms of viral infection and progression to ARDS and sepsis.</p></sec></sec><sec id="Sec8"><title>Conclusion</title><p id="Par69">Highly pathogenic human CoVs pose a substantial threat to public health. There are basically two groups of patients upon exposure to CoV, with the majority developing a short duration of clinical symptoms and the minority experiencing severe disease characterized by pneumonia and ARDS. The elderly are disproportionately vulnerable to severe disease due to immunosenescence and comorbidities. It is likely that CoVs will continue to cross species and cause additional outbreaks in the future. Therefore, even if a vaccine is developed for prevention of COVID-19, it would not protect against the next outbreak of a novel virus. Therefore, there is a need to develop novel strategies, not only to control the current pandemic, but also to be prepared to prevent the next pandemic.</p><p id="Par70">Strategies to develop a vaccine to elicit neutralizing antibodies to SARS-CoV-2 are technically challenging&#x000a0;due to the conformational hiding of the receptor binding domain (RBD) and the ability of this virus to transfer cell-to-cell in syncytia and infect target cells in a ACE2- and protease-independent manner by pinocytosis, limiting environmental exposure needed for antibody neutralization activity. Development of an anti-viral vaccine against complex viruses, such a SARS-Cov-2, is likely to require a potent and broad T-cell response to overcome viral escape mechanisms related to humoral immunity.</p><p id="Par71">A vaccine that elicits a robust cellular immune response requires identification of conserved viral epitopes and effective processing and presentation of viral antigens by APC on MHCI and MHCII in conjunction with co-stimulatory signals, as well as a diversity in the naive T cell repertoire. In addition, CTL memory cells resulting from vaccination will require infected cells to present the selected viral antigens in the vaccine on MHCI. Selection of common viral epitopes which present on MHC I (and MHC II) for vaccine development is technically difficult and CoV infection causes the down-regulation of MHC I on infected cells, making infected cells invisible to CTL. Since the elderly lack na&#x000ef;ve T-cells that are necessary for development of CTL with broad specificity to viral antigens, elderly would be less likely to respond efficiently to any future vaccine which targets cellular immunity.</p><p id="Par72">The rejection of allografts is one of the most conserved and powerful immune mechanisms, making priming with alloantigens an ideal candidate for use in vaccination of the elderly. AlloStim<sup>&#x000ae;</sup> is in use under a US FDA cleared IND and has been shown to readily be rejected by heavily pre-treated, immunosuppressed metastatic cancer patients. A phase I/II clinical trial protocol for use of AlloStim<sup>&#x000ae;</sup> in healthy elderly adults in currently under review by US FDA. Upon clearance, clinical trials could be initiated to evaluate this allo-priming concept in short order. For proof-of-concept, longitudinal PBMC samples are proposed to be collected pre- and post-allo-priming. The PBMC are to be pulsed with a panel of inactivated viruses or recombinant viral proteins to determine if they will non-specifically activate the allo-specific Th1/CTL memory cells. The supernatants from the viral-pulsed PBMC are proposed to be evaluated in live virus cytolytic plaque assays to determine if viral propagation is suppressed.</p><p id="Par73">Elderly persons are particularly susceptible to progressive viral disease and have delayed immune responses to viral infection due, at least in part, to immunosenescence, Th2 immune bias, decreased diversity of na&#x000ef;ve T-cells and high frequencies of exhausted memory cells from chronic inflammation (e.g., CMV). This results in a natural loss of the ability to mount effective innate and adaptive cellular immune responses to invading pathogens. The delayed and suppressed cellular immune response in the elderly enables viruses to become widely established and the resulting increased viral titers causes dys-regulated immune responses that can lead to a late,&#x000a0;over-active immune&#x000a0;response which can progress to pneumonitis, multiple organ failure and death.</p><p id="Par74">The key to an effective natural innate immune response that can limit the course of virus infection is the early production of type I/III interferons (IFN) and subsequent switch to type II IFN (IFN-&#x003d2;) production as the immune response matures. Successful viral infections become established due, in large part, to delayed innate immune responses and viral-mediated suppression of type I/III IFN production, allowing for rapid viral propagation which eventually results in dys-regulated immune responses which are correlated with tissue destruction, co-infection, multiple organ failure and death.</p><p id="Par75">To prevent accumulation of high viral burden in the elderly upon viral infection, allo-priming provides a mechanism whereby a ready pool of de-novo primed T-cells are in circulation that can respond rapidly to viral infection by producing IFN-&#x003d2;. The presence of non-exhausted Th1/CTL memory immune cells will modify the elderly immune character by providing a Th1 re-balancing mechanism in the memory cell compartment. This is accomplished through the creation of a high titer of polyclonal, allo-specific, non-exhausted, memory Th1/CTL T-cells through intradermal injections of activated allogeneic Th1-like cells (AlloStim<sup>&#x000ae;</sup>). The allo-specific memory cells resulting from the priming are programmed to produce IFN-&#x003d2; upon activation. IFN-&#x003d2; has a direct anti-viral effect on cells infected with virus and can also protect uninfected cells from infection. IFN-&#x003d2; creates the same anti-viral environment as innate release of Type I/III IFN does in an effective natural innate immune response.</p><p id="Par76">These allo-specific memory cells are capable of cross-reacting with foreign viral antigens and can be readily activated non-specifically by environmental stimuli such as cytokines and foreign pathogens. The memory pool of allo-specific immune cells in primed individuals can also be re-activated by additional intradermal or intravenous infusion of AlloStim<sup>&#x000ae;</sup> allogeneic cells upon first symptoms of viral disease. The by-stander effect of allo-specific Th1/CTL memory T-cell activation and IFN-&#x003d2; production is predicted to elicit protective effects on cells in the respiratory tract and generate rapid immune-mediated viral clearance as well as condition the microenvironment in infected tissues (e.g., lung epithelial cells) for an in situ vaccination leading to viral-specific immunity and memory that is specific for the invading virus. The heterologous immune effect can amplify the pan-viral protection upon each viral encounter, providing the possibility of long-term protection.</p><p id="Par77">The proposed alloantigen priming strategy can also be used in conjunction with any viral-specific vaccines. Co-injection of allo-specific and viral specific antigens could accelerate the adaptive cellular immune response to a known virus and serve as a means to enhance response to vaccines in the elderly. Subsequent injection of allogeneic cells will stimulate an allo-rejection memory recall response which can non-specifically activate resident viral-specific cells elicited by vaccination. This dual activation provides a mechanism to upregulate MHCI on infected targets, making the memory cells elicited by viral-specific vaccination able to identify and kill viral infected targets. The combination approach also has the advantage of overcoming the narrow immunity conferred by a single peptide vaccine by incorporating the in situ vaccination mechanism to elicit broad viral-specific cellular immune responses.</p><p id="Par78">This allo-priming mechanism can also be used as a counter-measure to bio-terrorism and bio-economic terrorism. Individuals that have been primed with alloantigen could be treated with an emergency injection of alloantigen to activate innate immunity and initiate the cascade of immune events leading to clearance of an unknown pathogen. Alloantigen could be provided in syringes for emergency ID injection upon concern for bioweapon exposure or first occurrence of symptoms, much in the same manner as epinephrine is provided to prevent anaphylactic shock.</p><p id="Par79">While finding methods to treat and prevent COVID19 infection is of urgent priority, it is also important to consider that the current pandemic is the third major outbreak of a novel coronaviral infection in humans within the past 20&#x000a0;years. Currently there are no registered vaccines or means of therapeutic protection against the prior SARS or MERS outbreaks available anywhere in the world. This is despite considerable efforts from experts worldwide to develop vaccines. The same technical obstacles preventing development of specific vaccines and treatments for these past CoV outbreaks likely also exist for development of a vaccine for the current COVID-19 viral pandemic. However, even if an effective vaccine is developed, it is estimated that it will take at least a year to complete clinical testing sufficient to obtain regulatory approval. If COVID-19 fades as did SARS and MERS, by the time a vaccine is available it will no longer be as urgent.</p><p id="Par80">However, protection of the vulnerable elderly population from the next pandemic and protecting the world economy from natural and bioweapon threats will remain an urgent need. Therefore, novel approaches to addressing the problem of new emerging viral epidemics, especially in the vulnerable elderly population, are of a high priority. Allo-priming holds promise as such an approach.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ARDS</term><def><p id="Par3">Acute respiratory distress syndrome</p></def></def-item><def-item><term>CMV</term><def><p id="Par4">Cytomegalovirus</p></def></def-item><def-item><term>CoV</term><def><p id="Par5">Coronavirus</p></def></def-item><def-item><term>CTL</term><def><p id="Par6">Cytotoxic T-lymphocyte</p></def></def-item><def-item><term>CCL-</term><def><p id="Par7">C&#x02013;C motif ligand</p></def></def-item><def-item><term>CxCL-</term><def><p id="Par8">CxC motif ligand</p></def></def-item><def-item><term>DAMP</term><def><p id="Par9">Danger associated molecular pattern</p></def></def-item><def-item><term>DC</term><def><p id="Par10">Dendritic cell</p></def></def-item><def-item><term>FDA</term><def><p id="Par11">Food and Drug Administration</p></def></def-item><def-item><term>GM-CSF</term><def><p id="Par12">Granulocyte-macrophage colony stimulating factor</p></def></def-item><def-item><term>GRP</term><def><p id="Par13">Glucose-regulated protein</p></def></def-item><def-item><term>GVHD</term><def><p id="Par14">Graft vs. host disease</p></def></def-item><def-item><term>GVT</term><def><p id="Par15">Graft vs. tumor</p></def></def-item><def-item><term>HIV</term><def><p id="Par16">Human immunodeficiency virus</p></def></def-item><def-item><term>HCV</term><def><p id="Par17">Hepatitis C virus</p></def></def-item><def-item><term>HSP</term><def><p id="Par18">Heat shock protein</p></def></def-item><def-item><term>ID</term><def><p id="Par19">Intradermal</p></def></def-item><def-item><term>IFN</term><def><p id="Par20">Interferon</p></def></def-item><def-item><term>IL</term><def><p id="Par21">Interleukin</p></def></def-item><def-item><term>IND</term><def><p id="Par22">Investigational New Drug</p></def></def-item><def-item><term>MDSC</term><def><p id="Par23">Myeloid-derived suppressor cell</p></def></def-item><def-item><term>MERS</term><def><p id="Par24">Middle East Respiratory Syndrome</p></def></def-item><def-item><term>MHC</term><def><p id="Par25">Major histocompatibility complex</p></def></def-item><def-item><term>NK</term><def><p id="Par26">Natural killer cell</p></def></def-item><def-item><term>NKT</term><def><p id="Par27">Natural killer T cell</p></def></def-item><def-item><term>US</term><def><p id="Par28">United States</p></def></def-item><def-item><term>SARS</term><def><p id="Par29">Severe acute respiratory syndrome</p></def></def-item><def-item><term>Th1</term><def><p id="Par30">T-helper 1</p></def></def-item><def-item><term>TNF</term><def><p id="Par31">Tumor necrosis factor</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>MHN conceived of the allopriming concept and wrote the manuscript. RO reviewed and edited the manuscript. Both authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>Not applicable.</p></notes><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par81">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par82">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par83">MHN is the Founder of Immunovative Therapies, Ltd. and Mirror Biologics, Inc which own patent rights to AlloStim<sup>&#x000ae;</sup>.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Operschall</surname><given-names>E</given-names></name><name><surname>Pavlovic</surname><given-names>J</given-names></name><name><surname>Nawrath</surname><given-names>M</given-names></name><name><surname>Molling</surname><given-names>K</given-names></name></person-group><article-title>Mechanism of protection against influenza A virus by DNA vaccine encoding the hemagglutinin gene</article-title><source>Intervirology</source><year>2000</year><volume>43</volume><fpage>322</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1159/000054000</pub-id><?supplied-pmid 11251388?><pub-id pub-id-type="pmid">11251388</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrat</surname><given-names>F</given-names></name><name><surname>Flahault</surname><given-names>A</given-names></name></person-group><article-title>Influenza vaccine: the challenge of antigenic drift</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>6852</fpage><lpage>6862</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.07.027</pub-id><?supplied-pmid 17719149?><pub-id pub-id-type="pmid">17719149</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forster</surname><given-names>P</given-names></name><name><surname>Forster</surname><given-names>L</given-names></name><name><surname>Renfrew</surname><given-names>C</given-names></name><name><surname>Forster</surname><given-names>M</given-names></name></person-group><article-title>Phylogenetic network analysis of SARS-CoV-2 genomes</article-title><source>Proc Natl Acad Sci USA</source><year>2020</year><volume>117</volume><fpage>9241</fpage><lpage>9243</lpage><pub-id pub-id-type="doi">10.1073/pnas.2004999117</pub-id><?supplied-pmid 32269081?><pub-id pub-id-type="pmid">32269081</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oxenius</surname><given-names>A</given-names></name><name><surname>Price</surname><given-names>DA</given-names></name><name><surname>Hersberger</surname><given-names>M</given-names></name><name><surname>Schlaepfer</surname><given-names>E</given-names></name><name><surname>Weber</surname><given-names>R</given-names></name><name><surname>Weber</surname><given-names>M</given-names></name><name><surname>Kundig</surname><given-names>TM</given-names></name><name><surname>Boni</surname><given-names>J</given-names></name><name><surname>Joller</surname><given-names>H</given-names></name><name><surname>Phillips</surname><given-names>RE</given-names></name><etal/></person-group><article-title>HIV-specific cellular immune response is inversely correlated with disease progression as defined by decline of CD4+ T cells in relation to HIV RNA load</article-title><source>J Infect Dis</source><year>2004</year><volume>189</volume><fpage>1199</fpage><lpage>1208</lpage><pub-id pub-id-type="doi">10.1086/382028</pub-id><?supplied-pmid 15031788?><pub-id pub-id-type="pmid">15031788</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>I</given-names></name><name><surname>Imawari</surname><given-names>M</given-names></name></person-group><article-title>Cellular immune response in HCV infection</article-title><source>J Gastroenterol</source><year>2000</year><volume>35</volume><fpage>881</fpage><lpage>889</lpage><pub-id pub-id-type="doi">10.1007/s005350070001</pub-id><?supplied-pmid 11573723?><pub-id pub-id-type="pmid">11573723</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kash</surname><given-names>JC</given-names></name><name><surname>Muhlberger</surname><given-names>E</given-names></name><name><surname>Carter</surname><given-names>V</given-names></name><name><surname>Grosch</surname><given-names>M</given-names></name><name><surname>Perwitasari</surname><given-names>O</given-names></name><name><surname>Proll</surname><given-names>SC</given-names></name><name><surname>Thomas</surname><given-names>MJ</given-names></name><name><surname>Weber</surname><given-names>F</given-names></name><name><surname>Klenk</surname><given-names>HD</given-names></name><name><surname>Katze</surname><given-names>MG</given-names></name></person-group><article-title>Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence</article-title><source>J Virol</source><year>2006</year><volume>80</volume><fpage>3009</fpage><lpage>3020</lpage><pub-id pub-id-type="doi">10.1128/JVI.80.6.3009-3020.2006</pub-id><?supplied-pmid 16501110?><pub-id pub-id-type="pmid">16501110</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cassaniti</surname><given-names>I</given-names></name><name><surname>Percivalle</surname><given-names>E</given-names></name><name><surname>Adzasehoun</surname><given-names>KMG</given-names></name><name><surname>Comolli</surname><given-names>G</given-names></name><name><surname>Baldanti</surname><given-names>F</given-names></name></person-group><article-title>Dengue virus-specific humoral and T cellular immune response in italian residents and travelers returning from endemic areas</article-title><source>Vector Borne Zoonotic Dis</source><year>2020</year><volume>20</volume><fpage>295</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1089/vbz.2019.2515</pub-id><?supplied-pmid 31821105?><pub-id pub-id-type="pmid">31821105</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Lau</surname><given-names>YF</given-names></name><name><surname>Lamirande</surname><given-names>EW</given-names></name><name><surname>Paddock</surname><given-names>CD</given-names></name><name><surname>Bartlett</surname><given-names>JH</given-names></name><name><surname>Zaki</surname><given-names>SR</given-names></name><name><surname>Subbarao</surname><given-names>K</given-names></name></person-group><article-title>Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection</article-title><source>J Virol</source><year>2010</year><volume>84</volume><fpage>1289</fpage><lpage>1301</lpage><pub-id pub-id-type="doi">10.1128/JVI.01281-09</pub-id><?supplied-pmid 19906920?><pub-id pub-id-type="pmid">19906920</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Lei</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>Z</given-names></name><name><surname>Peng</surname><given-names>L</given-names></name></person-group><article-title>Recurrence of positive SARS-CoV-2 RNA in COVID-19: a case report</article-title><source>Int J Infect Dis</source><year>2020</year><volume>93</volume><fpage>297</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2020.03.003</pub-id><?supplied-pmid 32147538?><pub-id pub-id-type="pmid">32147538</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panagioti</surname><given-names>E</given-names></name><name><surname>Klenerman</surname><given-names>P</given-names></name><name><surname>Lee</surname><given-names>LN</given-names></name><name><surname>van der Burg</surname><given-names>SH</given-names></name><name><surname>Arens</surname><given-names>R</given-names></name></person-group><article-title>Features of effective T cell-inducing vaccines against chronic viral infections</article-title><source>Front Immunol</source><year>2018</year><volume>9</volume><fpage>276</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.00276</pub-id><?supplied-pmid 29503649?><pub-id pub-id-type="pmid">29503649</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clemens</surname><given-names>EB</given-names></name><name><surname>van de Sandt</surname><given-names>C</given-names></name><name><surname>Wong</surname><given-names>SS</given-names></name><name><surname>Wakim</surname><given-names>LM</given-names></name><name><surname>Valkenburg</surname><given-names>SA</given-names></name></person-group><article-title>Harnessing the power of T cells: the promising hope for a universal influenza vaccine</article-title><source>Vaccines</source><year>2018</year><volume>6</volume><issue>2</issue><fpage>18</fpage><pub-id pub-id-type="doi">10.3390/vaccines6020018</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirkwood</surname><given-names>KL</given-names></name></person-group><article-title>Inflammaging</article-title><source>Immunol Invest</source><year>2018</year><volume>47</volume><fpage>770</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1080/08820139.2018.1552392</pub-id><?supplied-pmid 31282801?><pub-id pub-id-type="pmid">31282801</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ventura</surname><given-names>MT</given-names></name><name><surname>Casciaro</surname><given-names>M</given-names></name><name><surname>Gangemi</surname><given-names>S</given-names></name><name><surname>Buquicchio</surname><given-names>R</given-names></name></person-group><article-title>Immunosenescence in aging: between immune cells depletion and cytokines up-regulation</article-title><source>Clin Mol Allergy</source><year>2017</year><volume>15</volume><fpage>21</fpage><pub-id pub-id-type="doi">10.1186/s12948-017-0077-0</pub-id><?supplied-pmid 29259496?><pub-id pub-id-type="pmid">29259496</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dosch</surname><given-names>SF</given-names></name><name><surname>Mahajan</surname><given-names>SD</given-names></name><name><surname>Collins</surname><given-names>AR</given-names></name></person-group><article-title>SARS coronavirus spike protein-induced innate immune response occurs via activation of the NF-kappaB pathway in human monocyte macrophages in vitro</article-title><source>Virus Res</source><year>2009</year><volume>142</volume><fpage>19</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2009.01.005</pub-id><?supplied-pmid 19185596?><pub-id pub-id-type="pmid">19185596</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horvath</surname><given-names>CM</given-names></name><name><surname>Darnell</surname><given-names>JE</given-names><suffix>Jr</suffix></name></person-group><article-title>The antiviral state induced by alpha interferon and gamma interferon requires transcriptionally active Stat1 protein</article-title><source>J Virol</source><year>1996</year><volume>70</volume><fpage>647</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1128/JVI.70.1.647-650.1996</pub-id><?supplied-pmid 8523587?><pub-id pub-id-type="pmid">8523587</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>ZJ</given-names></name></person-group><article-title>Intrinsic antiviral immunity</article-title><source>Nat Immunol</source><year>2012</year><volume>13</volume><fpage>214</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1038/ni.2229</pub-id><?supplied-pmid 22344284?><pub-id pub-id-type="pmid">22344284</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cornberg</surname><given-names>M</given-names></name><name><surname>Clute</surname><given-names>SC</given-names></name><name><surname>Watkin</surname><given-names>LB</given-names></name><name><surname>Saccoccio</surname><given-names>FM</given-names></name><name><surname>Kim</surname><given-names>SK</given-names></name><name><surname>Naumov</surname><given-names>YN</given-names></name><name><surname>Brehm</surname><given-names>MA</given-names></name><name><surname>Aslan</surname><given-names>N</given-names></name><name><surname>Welsh</surname><given-names>RM</given-names></name><name><surname>Selin</surname><given-names>LK</given-names></name></person-group><article-title>CD8 T cell cross-reactivity networks mediate heterologous immunity in human EBV and murine vaccinia virus infections</article-title><source>J Immunol</source><year>2010</year><volume>184</volume><fpage>2825</fpage><lpage>2838</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0902168</pub-id><?supplied-pmid 20164414?><pub-id pub-id-type="pmid">20164414</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallucci</surname><given-names>S</given-names></name><name><surname>Matzinger</surname><given-names>P</given-names></name></person-group><article-title>Danger signals: SOS to the immune system</article-title><source>Curr Opin Immunol</source><year>2001</year><volume>13</volume><fpage>114</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/S0952-7915(00)00191-6</pub-id><?supplied-pmid 11154927?><pub-id pub-id-type="pmid">11154927</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breloer</surname><given-names>M</given-names></name><name><surname>Dorner</surname><given-names>B</given-names></name><name><surname>More</surname><given-names>SH</given-names></name><name><surname>Roderian</surname><given-names>T</given-names></name><name><surname>Fleischer</surname><given-names>B</given-names></name><name><surname>von Bonin</surname><given-names>A</given-names></name></person-group><article-title>Heat shock proteins as &#x0201c;danger signals&#x0201d;: eukaryotic Hsp60 enhances and accelerates antigen-specific IFN-gamma production in T cells</article-title><source>Eur J Immunol</source><year>2001</year><volume>31</volume><fpage>2051</fpage><lpage>2059</lpage><pub-id pub-id-type="doi">10.1002/1521-4141(200107)31:7&#x0003c;2051::AID-IMMU2051&#x0003e;3.0.CO;2-H</pub-id><?supplied-pmid 11449358?><pub-id pub-id-type="pmid">11449358</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wati</surname><given-names>S</given-names></name><name><surname>Soo</surname><given-names>ML</given-names></name><name><surname>Zilm</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Paton</surname><given-names>AW</given-names></name><name><surname>Burrell</surname><given-names>CJ</given-names></name><name><surname>Beard</surname><given-names>M</given-names></name><name><surname>Carr</surname><given-names>JM</given-names></name></person-group><article-title>Dengue virus infection induces upregulation of GRP78, which acts to chaperone viral antigen production</article-title><source>J Virol</source><year>2009</year><volume>83</volume><fpage>12871</fpage><lpage>12880</lpage><pub-id pub-id-type="doi">10.1128/JVI.01419-09</pub-id><?supplied-pmid 19793816?><pub-id pub-id-type="pmid">19793816</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menoret</surname><given-names>A</given-names></name></person-group><article-title>Purification of recombinant and endogenous HSP70s</article-title><source>Methods</source><year>2004</year><volume>32</volume><fpage>7</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/S1046-2023(03)00180-4</pub-id><?supplied-pmid 14624870?><pub-id pub-id-type="pmid">14624870</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Mosser</surname><given-names>DM</given-names></name></person-group><article-title>Macrophage activation by endogenous danger signals</article-title><source>J Pathol</source><year>2008</year><volume>214</volume><fpage>161</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1002/path.2284</pub-id><?supplied-pmid 18161744?><pub-id pub-id-type="pmid">18161744</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fournier</surname><given-names>P</given-names></name><name><surname>Arnold</surname><given-names>A</given-names></name><name><surname>Schirrmacher</surname><given-names>V</given-names></name></person-group><article-title>Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with newcastle disease virus</article-title><source>J BUON</source><year>2009</year><volume>14</volume><issue>Suppl 1</issue><fpage>S111</fpage><lpage>S122</lpage><?supplied-pmid 19785053?><pub-id pub-id-type="pmid">19785053</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berberich</surname><given-names>C</given-names></name><name><surname>Ramirez-Pineda</surname><given-names>JR</given-names></name><name><surname>Hambrecht</surname><given-names>C</given-names></name><name><surname>Alber</surname><given-names>G</given-names></name><name><surname>Skeiky</surname><given-names>YA</given-names></name><name><surname>Moll</surname><given-names>H</given-names></name></person-group><article-title>Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens</article-title><source>J Immunol</source><year>2003</year><volume>170</volume><fpage>3171</fpage><lpage>3179</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.170.6.3171</pub-id><?supplied-pmid 12626575?><pub-id pub-id-type="pmid">12626575</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahuja</surname><given-names>SS</given-names></name><name><surname>Mummidi</surname><given-names>S</given-names></name><name><surname>Malech</surname><given-names>HL</given-names></name><name><surname>Ahuja</surname><given-names>SK</given-names></name></person-group><article-title>Human dendritic cell (DC)-based anti-infective therapy: engineering DCs to secrete functional IFN-gamma and IL-12</article-title><source>J Immunol</source><year>1998</year><volume>161</volume><fpage>868</fpage><lpage>876</lpage><?supplied-pmid 9670965?><pub-id pub-id-type="pmid">9670965</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Xiang</surname><given-names>Z</given-names></name><name><surname>Ertl</surname><given-names>HC</given-names></name><name><surname>Wilson</surname><given-names>JM</given-names></name></person-group><article-title>Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo</article-title><source>Proc Natl Acad Sci USA</source><year>1995</year><volume>92</volume><fpage>7257</fpage><lpage>7261</lpage><pub-id pub-id-type="doi">10.1073/pnas.92.16.7257</pub-id><?supplied-pmid 7638177?><pub-id pub-id-type="pmid">7638177</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welsh</surname><given-names>RM</given-names></name><name><surname>Che</surname><given-names>JW</given-names></name><name><surname>Brehm</surname><given-names>MA</given-names></name><name><surname>Selin</surname><given-names>LK</given-names></name></person-group><article-title>Heterologous immunity between viruses</article-title><source>Immunol Rev</source><year>2010</year><volume>235</volume><fpage>244</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1111/j.0105-2896.2010.00897.x</pub-id><?supplied-pmid 20536568?><pub-id pub-id-type="pmid">20536568</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Messina</surname><given-names>NL</given-names></name><name><surname>Zimmermann</surname><given-names>P</given-names></name><name><surname>Curtis</surname><given-names>N</given-names></name></person-group><article-title>The impact of vaccines on heterologous adaptive immunity</article-title><source>Clin Microbiol Infect</source><year>2019</year><volume>25</volume><fpage>1484</fpage><lpage>1493</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2019.02.016</pub-id><?supplied-pmid 30797062?><pub-id pub-id-type="pmid">30797062</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marino</surname><given-names>J</given-names></name><name><surname>Paster</surname><given-names>J</given-names></name><name><surname>Benichou</surname><given-names>G</given-names></name></person-group><article-title>Allorecognition by T lymphocytes and allograft rejection</article-title><source>Front Immunol</source><year>2016</year><volume>7</volume><fpage>582</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2016.00582</pub-id><?supplied-pmid 28018349?><pub-id pub-id-type="pmid">28018349</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Har-Noy</surname><given-names>M</given-names></name><name><surname>Zeira</surname><given-names>M</given-names></name><name><surname>Weiss</surname><given-names>L</given-names></name><name><surname>Fingerut</surname><given-names>E</given-names></name><name><surname>Or</surname><given-names>R</given-names></name><name><surname>Slavin</surname><given-names>S</given-names></name></person-group><article-title>Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma</article-title><source>Leuk Res</source><year>2009</year><volume>33</volume><fpage>525</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1016/j.leukres.2008.08.017</pub-id><?supplied-pmid 18834631?><pub-id pub-id-type="pmid">18834631</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Har-Noy</surname><given-names>M</given-names></name><name><surname>Zeira</surname><given-names>M</given-names></name><name><surname>Weiss</surname><given-names>L</given-names></name><name><surname>Slavin</surname><given-names>S</given-names></name></person-group><article-title>Completely mismatched allogeneic CD3/CD28 cross-linked Th1 memory cells elicit anti-leukemia effects in unconditioned hosts without GVHD toxicity</article-title><source>Leuk Res</source><year>2008</year><volume>32</volume><fpage>1903</fpage><lpage>1913</lpage><pub-id pub-id-type="doi">10.1016/j.leukres.2008.05.007</pub-id><?supplied-pmid 18565579?><pub-id pub-id-type="pmid">18565579</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Har-Noy</surname><given-names>M</given-names></name><name><surname>Sukeepaisarnjaroen</surname><given-names>W</given-names></name><name><surname>Lausoontornsiri</surname><given-names>W</given-names></name><name><surname>Wittenberg</surname><given-names>A</given-names></name><name><surname>Bloch</surname><given-names>M</given-names></name><name><surname>Sonnenfeld</surname><given-names>T</given-names></name><name><surname>Fingerut</surname><given-names>E</given-names></name><name><surname>Kaminer</surname><given-names>Y</given-names></name><name><surname>Ahooja</surname><given-names>A</given-names></name><name><surname>Wongwiwatchai</surname><given-names>J</given-names></name><etal/></person-group><article-title>Individualized cancer vaccine to elicit tumor debulking immunity in advanced HCC</article-title><source>J Clin Oncol</source><year>2018</year><volume>36</volume><fpage>e15054</fpage><pub-id pub-id-type="doi">10.1200/JCO.2018.36.15_suppl.e15054</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Har-Noy</surname><given-names>M</given-names></name><name><surname>Lausoontornsiri</surname><given-names>W</given-names></name><name><surname>Or</surname><given-names>R</given-names></name><name><surname>Katsanis</surname><given-names>E</given-names></name></person-group><article-title>Response of HER2+ breast cancer patients to allogeneic cell immunotherapy</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><fpage>e13013</fpage><pub-id pub-id-type="doi">10.1200/jco.2012.30.15_suppl.e13013</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Epple</surname><given-names>LM</given-names></name><name><surname>Bemis</surname><given-names>LT</given-names></name><name><surname>Cavanaugh</surname><given-names>RP</given-names></name><name><surname>Skope</surname><given-names>A</given-names></name><name><surname>Mayer-Sonnenfeld</surname><given-names>T</given-names></name><name><surname>Frank</surname><given-names>C</given-names></name><name><surname>Olver</surname><given-names>CS</given-names></name><name><surname>Lencioni</surname><given-names>AM</given-names></name><name><surname>Dusto</surname><given-names>NL</given-names></name><name><surname>Tal</surname><given-names>A</given-names></name><etal/></person-group><article-title>Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine</article-title><source>Int J Hyperth</source><year>2013</year><volume>29</volume><fpage>390</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.3109/02656736.2013.800997</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayer-Sonnenfeld</surname><given-names>T</given-names></name><name><surname>Har-Noy</surname><given-names>M</given-names></name><name><surname>Lillehei</surname><given-names>KO</given-names></name><name><surname>Graner</surname><given-names>MW</given-names></name></person-group><article-title>Proteomic analyses of different human tumour-derived chaperone-rich cell lysate (CRCL) anti-cancer vaccines reveal antigen content and strong similarities amongst the vaccines along with a basis for CRCL&#x02019;s unique structure: CRCL vaccine proteome leads to unique structure</article-title><source>Int J Hyperth</source><year>2013</year><volume>29</volume><fpage>520</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.3109/02656736.2013.796529</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LaCasse</surname><given-names>CJ</given-names></name><name><surname>Janikashvili</surname><given-names>N</given-names></name><name><surname>Larmonier</surname><given-names>CB</given-names></name><name><surname>Alizadeh</surname><given-names>D</given-names></name><name><surname>Hanke</surname><given-names>N</given-names></name><name><surname>Kartchner</surname><given-names>J</given-names></name><name><surname>Situ</surname><given-names>E</given-names></name><name><surname>Centuori</surname><given-names>S</given-names></name><name><surname>Har-Noy</surname><given-names>M</given-names></name><name><surname>Bonnotte</surname><given-names>B</given-names></name><etal/></person-group><article-title>Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN-gamma-dependent mechanism</article-title><source>J Immunol</source><year>2011</year><volume>187</volume><fpage>6310</fpage><lpage>6317</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1101812</pub-id><?supplied-pmid 22075702?><pub-id pub-id-type="pmid">22075702</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janikashvili</surname><given-names>N</given-names></name><name><surname>LaCasse</surname><given-names>CJ</given-names></name><name><surname>Larmonier</surname><given-names>C</given-names></name><name><surname>Trad</surname><given-names>M</given-names></name><name><surname>Herrell</surname><given-names>A</given-names></name><name><surname>Bustamante</surname><given-names>S</given-names></name><name><surname>Bonnotte</surname><given-names>B</given-names></name><name><surname>Har-Noy</surname><given-names>M</given-names></name><name><surname>Larmonier</surname><given-names>N</given-names></name><name><surname>Katsanis</surname><given-names>E</given-names></name></person-group><article-title>Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia</article-title><source>Blood</source><year>2011</year><volume>117</volume><fpage>1555</fpage><lpage>1564</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-06-288621</pub-id><?supplied-pmid 21123824?><pub-id pub-id-type="pmid">21123824</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Har-Noy</surname><given-names>M</given-names></name><name><surname>Slavin</surname><given-names>S</given-names></name></person-group><article-title>The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement?</article-title><source>Med Hypotheses</source><year>2008</year><volume>70</volume><fpage>1186</fpage><lpage>1192</lpage><pub-id pub-id-type="doi">10.1016/j.mehy.2007.10.008</pub-id><?supplied-pmid 18054441?><pub-id pub-id-type="pmid">18054441</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richters</surname><given-names>CD</given-names></name><name><surname>Hoekstra</surname><given-names>MJ</given-names></name><name><surname>du Pont</surname><given-names>JS</given-names></name><name><surname>Kreis</surname><given-names>RW</given-names></name><name><surname>Kamperdijk</surname><given-names>EW</given-names></name></person-group><article-title>Immunology of skin transplantation</article-title><source>Clin Dermatol</source><year>2005</year><volume>23</volume><fpage>338</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1016/j.clindermatol.2004.07.022</pub-id><?supplied-pmid 16023928?><pub-id pub-id-type="pmid">16023928</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bangs</surname><given-names>SC</given-names></name><name><surname>Baban</surname><given-names>D</given-names></name><name><surname>Cattan</surname><given-names>HJ</given-names></name><name><surname>Li</surname><given-names>CK</given-names></name><name><surname>McMichael</surname><given-names>AJ</given-names></name><name><surname>Xu</surname><given-names>XN</given-names></name></person-group><article-title>Human CD4+ memory T cells are preferential targets for bystander activation and apoptosis</article-title><source>J Immunol</source><year>2009</year><volume>182</volume><fpage>1962</fpage><lpage>1971</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0802596</pub-id><?supplied-pmid 19201849?><pub-id pub-id-type="pmid">19201849</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eberl</surname><given-names>G</given-names></name><name><surname>Brawand</surname><given-names>P</given-names></name><name><surname>MacDonald</surname><given-names>HR</given-names></name></person-group><article-title>Selective bystander proliferation of memory CD4+ and CD8+ T cells upon NK T or T cell activation</article-title><source>J Immunol</source><year>2000</year><volume>165</volume><fpage>4305</fpage><lpage>4311</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.165.8.4305</pub-id><?supplied-pmid 11035065?><pub-id pub-id-type="pmid">11035065</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manser</surname><given-names>AR</given-names></name><name><surname>Uhrberg</surname><given-names>M</given-names></name></person-group><article-title>Age-related changes in natural killer cell repertoires: impact on NK cell function and immune surveillance</article-title><source>Cancer Immunol Immunother</source><year>2016</year><volume>65</volume><fpage>417</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1007/s00262-015-1750-0</pub-id><?supplied-pmid 26288343?><pub-id pub-id-type="pmid">26288343</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Demirci</surname><given-names>G</given-names></name><name><surname>Madsen</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>XC</given-names></name></person-group><article-title>Innate NK cells and macrophages recognize and reject allogeneic nonself in vivo via different mechanisms</article-title><source>J Immunol</source><year>2012</year><volume>188</volume><fpage>2703</fpage><lpage>2711</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1102997</pub-id><?supplied-pmid 22327074?><pub-id pub-id-type="pmid">22327074</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benichou</surname><given-names>G</given-names></name><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Yun</surname><given-names>SH</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Fray</surname><given-names>M</given-names></name><name><surname>Tocco</surname><given-names>G</given-names></name></person-group><article-title>Immune recognition and rejection of allogeneic skin grafts</article-title><source>Immunotherapy</source><year>2011</year><volume>3</volume><fpage>757</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.2217/imt.11.2</pub-id><?supplied-pmid 21668313?><pub-id pub-id-type="pmid">21668313</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ongradi</surname><given-names>J</given-names></name><name><surname>Kovesdi</surname><given-names>V</given-names></name></person-group><article-title>Factors that may impact on immunosenescence: an appraisal</article-title><source>Immun Ageing</source><year>2010</year><volume>7</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/1742-4933-7-7</pub-id><?supplied-pmid 20546588?><pub-id pub-id-type="pmid">20546588</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Targonski</surname><given-names>PV</given-names></name><name><surname>Jacobson</surname><given-names>RM</given-names></name><name><surname>Poland</surname><given-names>GA</given-names></name></person-group><article-title>Immunosenescence: role and measurement in influenza vaccine response among the elderly</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>3066</fpage><lpage>3069</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.01.025</pub-id><?supplied-pmid 17275144?><pub-id pub-id-type="pmid">17275144</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ongradi</surname><given-names>J</given-names></name><name><surname>Stercz</surname><given-names>B</given-names></name><name><surname>Kovesdi</surname><given-names>V</given-names></name><name><surname>Vertes</surname><given-names>L</given-names></name></person-group><article-title>Immunosenescence and vaccination of the elderly, I. Age-related immune impairment</article-title><source>Acta Microbiol Immunol Hung</source><year>2009</year><volume>56</volume><fpage>199</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1556/AMicr.56.2009.3.1</pub-id><?supplied-pmid 19789136?><pub-id pub-id-type="pmid">19789136</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falsey</surname><given-names>AR</given-names></name><name><surname>Walsh</surname><given-names>EE</given-names></name></person-group><article-title>Respiratory syncytial virus infection in elderly adults</article-title><source>Drugs Aging</source><year>2005</year><volume>22</volume><fpage>577</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.2165/00002512-200522070-00004</pub-id><?supplied-pmid 16038573?><pub-id pub-id-type="pmid">16038573</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falsey</surname><given-names>AR</given-names></name><name><surname>Hennessey</surname><given-names>PA</given-names></name><name><surname>Formica</surname><given-names>MA</given-names></name><name><surname>Cox</surname><given-names>C</given-names></name><name><surname>Walsh</surname><given-names>EE</given-names></name></person-group><article-title>Respiratory syncytial virus infection in elderly and high-risk adults</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><fpage>1749</fpage><lpage>1759</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa043951</pub-id><?supplied-pmid 15858184?><pub-id pub-id-type="pmid">15858184</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saxena</surname><given-names>AK</given-names></name><name><surname>Panhotra</surname><given-names>BR</given-names></name></person-group><article-title>The vulnerability of middle-aged and elderly patients to hepatitis C virus infection in a high-prevalence hospital-based hemodialysis setting</article-title><source>J Am Geriatr Soc</source><year>2004</year><volume>52</volume><fpage>242</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1111/j.1532-5415.2004.52062.x</pub-id><?supplied-pmid 14728634?><pub-id pub-id-type="pmid">14728634</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butt</surname><given-names>AA</given-names></name><name><surname>Dascomb</surname><given-names>KK</given-names></name><name><surname>DeSalvo</surname><given-names>KB</given-names></name><name><surname>Bazzano</surname><given-names>L</given-names></name><name><surname>Kissinger</surname><given-names>PJ</given-names></name><name><surname>Szerlip</surname><given-names>HM</given-names></name></person-group><article-title>Human immunodeficiency virus infection in elderly patients</article-title><source>South Med J</source><year>2001</year><volume>94</volume><fpage>397</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1097/00007611-200194040-00008</pub-id><?supplied-pmid 11332905?><pub-id pub-id-type="pmid">11332905</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcus</surname><given-names>EL</given-names></name><name><surname>Tur-Kaspa</surname><given-names>R</given-names></name></person-group><article-title>Epidemiology of hepatitis C virus infection in the elderly</article-title><source>Gerontology</source><year>2001</year><volume>47</volume><fpage>117</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1159/000052783</pub-id><?supplied-pmid 11287737?><pub-id pub-id-type="pmid">11287737</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunner</surname><given-names>S</given-names></name><name><surname>Herndler-Brandstetter</surname><given-names>D</given-names></name><name><surname>Weinberger</surname><given-names>B</given-names></name><name><surname>Grubeck-Loebenstein</surname><given-names>B</given-names></name></person-group><article-title>Persistent viral infections and immune aging</article-title><source>Ageing Res Rev</source><year>2011</year><volume>10</volume><fpage>362</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1016/j.arr.2010.08.003</pub-id><?supplied-pmid 20727987?><pub-id pub-id-type="pmid">20727987</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haq</surname><given-names>K</given-names></name><name><surname>McElhaney</surname><given-names>JE</given-names></name></person-group><article-title>Ageing and respiratory infections: the airway of ageing</article-title><source>Immunol Lett</source><year>2014</year><volume>162</volume><fpage>323</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1016/j.imlet.2014.06.009</pub-id><?supplied-pmid 24973652?><pub-id pub-id-type="pmid">24973652</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawelec</surname><given-names>G</given-names></name><name><surname>Adibzadeh</surname><given-names>M</given-names></name><name><surname>Solana</surname><given-names>R</given-names></name><name><surname>Beckman</surname><given-names>I</given-names></name></person-group><article-title>The T cell in the ageing individual</article-title><source>Mech Ageing Dev</source><year>1997</year><volume>93</volume><fpage>35</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/S0047-6374(96)01812-X</pub-id><?supplied-pmid 9089569?><pub-id pub-id-type="pmid">9089569</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>AE</given-names></name></person-group><article-title>Immunity and aging</article-title><source>Otolaryngol Clin N Am</source><year>1982</year><volume>15</volume><fpage>287</fpage><lpage>292</lpage></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>PA</given-names></name><name><surname>Bueno</surname><given-names>SM</given-names></name><name><surname>Riedel</surname><given-names>CA</given-names></name><name><surname>Kalergis</surname><given-names>AM</given-names></name></person-group><article-title>Impairment of T cell immunity by the respiratory syncytial virus: targeting virulence mechanisms for therapy and prophylaxis</article-title><source>Curr Med Chem</source><year>2009</year><volume>16</volume><fpage>4609</fpage><lpage>4625</lpage><pub-id pub-id-type="doi">10.2174/092986709789760724</pub-id><?supplied-pmid 19903147?><pub-id pub-id-type="pmid">19903147</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Fang</surname><given-names>M</given-names></name></person-group><article-title>Immunosenescence and age-related viral diseases</article-title><source>Sci China Life Sci</source><year>2013</year><volume>56</volume><fpage>399</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1007/s11427-013-4478-0</pub-id><?supplied-pmid 23633071?><pub-id pub-id-type="pmid">23633071</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bektas</surname><given-names>A</given-names></name><name><surname>Schurman</surname><given-names>SH</given-names></name><name><surname>Sen</surname><given-names>R</given-names></name><name><surname>Ferrucci</surname><given-names>L</given-names></name></person-group><article-title>Human T cell immunosenescence and inflammation in aging</article-title><source>J Leukoc Biol</source><year>2017</year><volume>102</volume><fpage>977</fpage><lpage>988</lpage><pub-id pub-id-type="doi">10.1189/jlb.3RI0716-335R</pub-id><?supplied-pmid 28733462?><pub-id pub-id-type="pmid">28733462</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pera</surname><given-names>A</given-names></name><name><surname>Campos</surname><given-names>C</given-names></name><name><surname>Lopez</surname><given-names>N</given-names></name><name><surname>Hassouneh</surname><given-names>F</given-names></name><name><surname>Alonso</surname><given-names>C</given-names></name><name><surname>Tarazona</surname><given-names>R</given-names></name><name><surname>Solana</surname><given-names>R</given-names></name></person-group><article-title>Immunosenescence: implications for response to infection and vaccination in older people</article-title><source>Maturitas</source><year>2015</year><volume>82</volume><fpage>50</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.maturitas.2015.05.004</pub-id><?supplied-pmid 26044074?><pub-id pub-id-type="pmid">26044074</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Lopez</surname><given-names>CB</given-names></name></person-group><article-title>The innate immune response to RSV: advances in our understanding of critical viral and host factors</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>481</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.09.030</pub-id><?supplied-pmid 27686836?><pub-id pub-id-type="pmid">27686836</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Lai</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Pan</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Coronavirus infections and immune responses</article-title><source>J Med Virol</source><year>2020</year><volume>92</volume><fpage>424</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1002/jmv.25685</pub-id><?supplied-pmid 31981224?><pub-id pub-id-type="pmid">31981224</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rink</surname><given-names>L</given-names></name><name><surname>Cakman</surname><given-names>I</given-names></name><name><surname>Kirchner</surname><given-names>H</given-names></name></person-group><article-title>Altered cytokine production in the elderly</article-title><source>Mech Ageing Dev</source><year>1998</year><volume>102</volume><fpage>199</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1016/S0047-6374(97)00153-X</pub-id><?supplied-pmid 9720652?><pub-id pub-id-type="pmid">9720652</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shearer</surname><given-names>GM</given-names></name></person-group><article-title>Th1/Th2 changes in aging</article-title><source>Mech Ageing Dev</source><year>1997</year><volume>94</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/S0047-6374(96)01849-0</pub-id><?supplied-pmid 9147355?><pub-id pub-id-type="pmid">9147355</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Jing</surname><given-names>Y</given-names></name><name><surname>Campbell</surname><given-names>AE</given-names></name><name><surname>Gravenstein</surname><given-names>S</given-names></name></person-group><article-title>Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly</article-title><source>J Immunol</source><year>2004</year><volume>172</volume><fpage>3437</fpage><lpage>3446</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.172.6.3437</pub-id><?supplied-pmid 15004143?><pub-id pub-id-type="pmid">15004143</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karanfilov</surname><given-names>CI</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Fox</surname><given-names>CC</given-names></name><name><surname>Lakshmanan</surname><given-names>RR</given-names></name><name><surname>Whisler</surname><given-names>RL</given-names></name></person-group><article-title>Age-related defects in Th1 and Th2 cytokine production by human T cells can be dissociated from altered frequencies of CD45RA+ and CD45RO+ T cell subsets</article-title><source>Mech Ageing Dev</source><year>1999</year><volume>109</volume><fpage>97</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/S0047-6374(99)00030-5</pub-id><?supplied-pmid 10515660?><pub-id pub-id-type="pmid">10515660</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akbar</surname><given-names>AN</given-names></name><name><surname>Fletcher</surname><given-names>JM</given-names></name></person-group><article-title>Memory T cell homeostasis and senescence during aging</article-title><source>Curr Opin Immunol</source><year>2005</year><volume>17</volume><fpage>480</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2005.07.019</pub-id><?supplied-pmid 16098721?><pub-id pub-id-type="pmid">16098721</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sansoni</surname><given-names>P</given-names></name><name><surname>Vescovini</surname><given-names>R</given-names></name><name><surname>Fagnoni</surname><given-names>F</given-names></name><name><surname>Biasini</surname><given-names>C</given-names></name><name><surname>Zanni</surname><given-names>F</given-names></name><name><surname>Zanlari</surname><given-names>L</given-names></name><name><surname>Telera</surname><given-names>A</given-names></name><name><surname>Lucchini</surname><given-names>G</given-names></name><name><surname>Passeri</surname><given-names>G</given-names></name><name><surname>Monti</surname><given-names>D</given-names></name><etal/></person-group><article-title>The immune system in extreme longevity</article-title><source>Exp Gerontol</source><year>2008</year><volume>43</volume><fpage>61</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.exger.2007.06.008</pub-id><?supplied-pmid 17870272?><pub-id pub-id-type="pmid">17870272</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saeidi</surname><given-names>A</given-names></name><name><surname>Zandi</surname><given-names>K</given-names></name><name><surname>Cheok</surname><given-names>YY</given-names></name><name><surname>Saeidi</surname><given-names>H</given-names></name><name><surname>Wong</surname><given-names>WF</given-names></name><name><surname>Lee</surname><given-names>CYQ</given-names></name><name><surname>Cheong</surname><given-names>HC</given-names></name><name><surname>Yong</surname><given-names>YK</given-names></name><name><surname>Larsson</surname><given-names>M</given-names></name><name><surname>Shankar</surname><given-names>EM</given-names></name></person-group><article-title>T-cell exhaustion in chronic infections: reversing the state of exhaustion and reinvigorating optimal protective immune responses</article-title><source>Front Immunol</source><year>2018</year><volume>9</volume><fpage>2569</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.02569</pub-id><?supplied-pmid 30473697?><pub-id pub-id-type="pmid">30473697</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henson</surname><given-names>SM</given-names></name><name><surname>Akbar</surname><given-names>AN</given-names></name></person-group><article-title>Memory T-cell homeostasis and senescence during aging</article-title><source>Adv Exp Med Biol</source><year>2010</year><volume>684</volume><fpage>189</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1007/978-1-4419-6451-9_15</pub-id><?supplied-pmid 20795550?><pub-id pub-id-type="pmid">20795550</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minato</surname><given-names>N</given-names></name><name><surname>Hattori</surname><given-names>M</given-names></name><name><surname>Hamazaki</surname><given-names>Y</given-names></name></person-group><article-title>Physiology and pathology of T-cell aging</article-title><source>Int Immunol</source><year>2020</year><volume>32</volume><fpage>223</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxaa006</pub-id><?supplied-pmid 31967307?><pub-id pub-id-type="pmid">31967307</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lepletier</surname><given-names>A</given-names></name><name><surname>Alsharif</surname><given-names>A</given-names></name><name><surname>Chidgey</surname><given-names>AP</given-names></name></person-group><article-title>Inflammation and thymus ageing</article-title><source>Front Horm Res</source><year>2017</year><volume>48</volume><fpage>19</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1159/000452903</pub-id><?supplied-pmid 28245449?><pub-id pub-id-type="pmid">28245449</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dugan</surname><given-names>HL</given-names></name><name><surname>Henry</surname><given-names>C</given-names></name><name><surname>Wilson</surname><given-names>PC</given-names></name></person-group><article-title>Aging and influenza vaccine-induced immunity</article-title><source>Cell Immunol</source><year>2020</year><volume>348</volume><fpage>103998</fpage><pub-id pub-id-type="doi">10.1016/j.cellimm.2019.103998</pub-id><?supplied-pmid 31733824?><pub-id pub-id-type="pmid">31733824</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>G</given-names></name><name><surname>Goodwin</surname><given-names>J</given-names></name></person-group><article-title>Effect of aging on respiratory system physiology and immunology</article-title><source>Clin Interv Aging</source><year>2006</year><volume>1</volume><fpage>253</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.2147/ciia.2006.1.3.253</pub-id><?supplied-pmid 18046878?><pub-id pub-id-type="pmid">18046878</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>SJ</given-names></name><name><surname>Lee</surname><given-names>JK</given-names></name><name><surname>Shin</surname><given-names>OS</given-names></name></person-group><article-title>Aging and the immune system: the impact of immunosenescence on viral infection, immunity and vaccine immunogenicity</article-title><source>Immune Netw</source><year>2019</year><volume>19</volume><fpage>e37</fpage><pub-id pub-id-type="doi">10.4110/in.2019.19.e37</pub-id><?supplied-pmid 31921467?><pub-id pub-id-type="pmid">31921467</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szucs</surname><given-names>T</given-names></name></person-group><article-title>The socio-economic burden of influenza</article-title><source>J Antimicrob Chemother</source><year>1999</year><volume>44</volume><issue>Suppl B</issue><fpage>11</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1093/jac/44.suppl_2.11</pub-id><?supplied-pmid 10877457?><pub-id pub-id-type="pmid">10877457</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maynard</surname><given-names>A</given-names></name><name><surname>Bloor</surname><given-names>K</given-names></name></person-group><article-title>The economic impact of pandemic influenza</article-title><source>BMJ</source><year>2009</year><volume>339</volume><fpage>b4888</fpage><pub-id pub-id-type="doi">10.1136/bmj.b4888</pub-id><?supplied-pmid 19926698?><pub-id pub-id-type="pmid">19926698</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roses</surname><given-names>M</given-names></name><name><surname>Bonvehi</surname><given-names>PE</given-names></name></person-group><article-title>Vaccines in adults</article-title><source>Medicina (B Aires)</source><year>2019</year><volume>79</volume><fpage>552</fpage><lpage>558</lpage><pub-id pub-id-type="pmid">31864225</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crooke</surname><given-names>SN</given-names></name><name><surname>Ovsyannikova</surname><given-names>IG</given-names></name><name><surname>Poland</surname><given-names>GA</given-names></name><name><surname>Kennedy</surname><given-names>RB</given-names></name></person-group><article-title>Immunosenescence and human vaccine immune responses</article-title><source>Immun Ageing</source><year>2019</year><volume>16</volume><fpage>25</fpage><pub-id pub-id-type="doi">10.1186/s12979-019-0164-9</pub-id><?supplied-pmid 31528180?><pub-id pub-id-type="pmid">31528180</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hakim</surname><given-names>FT</given-names></name><name><surname>Flomerfelt</surname><given-names>FA</given-names></name><name><surname>Boyiadzis</surname><given-names>M</given-names></name><name><surname>Gress</surname><given-names>RE</given-names></name></person-group><article-title>Aging, immunity and cancer</article-title><source>Curr Opin Immunol</source><year>2004</year><volume>16</volume><fpage>151</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2004.01.009</pub-id><?supplied-pmid 15023406?><pub-id pub-id-type="pmid">15023406</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>L</given-names></name><name><surname>Di Benedetto</surname><given-names>S</given-names></name><name><surname>Pawelec</surname><given-names>G</given-names></name></person-group><article-title>The immune system and its dysregulation with aging</article-title><source>Subcell Biochem</source><year>2019</year><volume>91</volume><fpage>21</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1007/978-981-13-3681-2_2</pub-id><?supplied-pmid 30888648?><pub-id pub-id-type="pmid">30888648</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadighi Akha</surname><given-names>AA</given-names></name></person-group><article-title>Aging and the immune system: an overview</article-title><source>J Immunol Methods</source><year>2018</year><volume>463</volume><fpage>21</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2018.08.005</pub-id><?supplied-pmid 30114401?><pub-id pub-id-type="pmid">30114401</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Yamane</surname><given-names>H</given-names></name><name><surname>Paul</surname><given-names>WE</given-names></name></person-group><article-title>Differentiation of effector CD4 T cell populations (*)</article-title><source>Annu Rev Immunol</source><year>2010</year><volume>28</volume><fpage>445</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-030409-101212</pub-id><?supplied-pmid 20192806?><pub-id pub-id-type="pmid">20192806</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stark</surname><given-names>GR</given-names></name><name><surname>Kerr</surname><given-names>IM</given-names></name><name><surname>Williams</surname><given-names>BR</given-names></name><name><surname>Silverman</surname><given-names>RH</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name></person-group><article-title>How cells respond to interferons</article-title><source>Annu Rev Biochem</source><year>1998</year><volume>67</volume><fpage>227</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1146/annurev.biochem.67.1.227</pub-id><?supplied-pmid 9759489?><pub-id pub-id-type="pmid">9759489</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>A</given-names></name><name><surname>Garner-Spitzer</surname><given-names>E</given-names></name><name><surname>Jasinska</surname><given-names>J</given-names></name><name><surname>Kollaritsch</surname><given-names>H</given-names></name><name><surname>Stiasny</surname><given-names>K</given-names></name><name><surname>Kundi</surname><given-names>M</given-names></name><name><surname>Wiedermann</surname><given-names>U</given-names></name></person-group><article-title>Age-related differences in humoral and cellular immune responses after primary immunisation: indications for stratified vaccination schedules</article-title><source>Sci Rep</source><year>2018</year><volume>8</volume><fpage>9825</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-28111-8</pub-id><?supplied-pmid 29959387?><pub-id pub-id-type="pmid">29959387</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>SKP</given-names></name><name><surname>Lau</surname><given-names>CCY</given-names></name><name><surname>Chan</surname><given-names>KH</given-names></name><name><surname>Li</surname><given-names>CPY</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Jin</surname><given-names>DY</given-names></name><name><surname>Chan</surname><given-names>JFW</given-names></name><name><surname>Woo</surname><given-names>PCY</given-names></name><name><surname>Yuen</surname><given-names>KY</given-names></name></person-group><article-title>Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment</article-title><source>J Gen Virol</source><year>2013</year><volume>94</volume><fpage>2679</fpage><lpage>2690</lpage><pub-id pub-id-type="doi">10.1099/vir.0.055533-0</pub-id><?supplied-pmid 24077366?><pub-id pub-id-type="pmid">24077366</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Channappanavar</surname><given-names>R</given-names></name><name><surname>Fehr</surname><given-names>AR</given-names></name><name><surname>Vijay</surname><given-names>R</given-names></name><name><surname>Mack</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Meyerholz</surname><given-names>DK</given-names></name><name><surname>Perlman</surname><given-names>S</given-names></name></person-group><article-title>Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice</article-title><source>Cell Host Microbe</source><year>2016</year><volume>19</volume><fpage>181</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2016.01.007</pub-id><?supplied-pmid 26867177?><pub-id pub-id-type="pmid">26867177</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Channappanavar</surname><given-names>R</given-names></name><name><surname>Perlman</surname><given-names>S</given-names></name></person-group><article-title>Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology</article-title><source>Semin Immunopathol</source><year>2017</year><volume>39</volume><fpage>529</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1007/s00281-017-0629-x</pub-id><?supplied-pmid 28466096?><pub-id pub-id-type="pmid">28466096</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>HM</given-names></name><name><surname>Hwang</surname><given-names>S</given-names></name></person-group><article-title>Direct antiviral mechanisms of interferon-gamma</article-title><source>Immune Netw</source><year>2018</year><volume>18</volume><fpage>e33</fpage><pub-id pub-id-type="doi">10.4110/in.2018.18.e33</pub-id><?supplied-pmid 30402328?><pub-id pub-id-type="pmid">30402328</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrestha</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Samuel</surname><given-names>MA</given-names></name><name><surname>Whitby</surname><given-names>K</given-names></name><name><surname>Craft</surname><given-names>J</given-names></name><name><surname>Fikrig</surname><given-names>E</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name></person-group><article-title>Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection</article-title><source>J Virol</source><year>2006</year><volume>80</volume><fpage>5338</fpage><lpage>5348</lpage><pub-id pub-id-type="doi">10.1128/JVI.00274-06</pub-id><?supplied-pmid 16699014?><pub-id pub-id-type="pmid">16699014</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>DE</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A</given-names></name></person-group><article-title>The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion</article-title><source>Cytokine Growth Factor Rev</source><year>2001</year><volume>12</volume><fpage>143</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/S1359-6101(00)00027-7</pub-id><?supplied-pmid 11325598?><pub-id pub-id-type="pmid">11325598</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaajetaan</surname><given-names>GR</given-names></name><name><surname>Geelen</surname><given-names>TH</given-names></name><name><surname>Vernooy</surname><given-names>JH</given-names></name><name><surname>Dentener</surname><given-names>MA</given-names></name><name><surname>Reynaert</surname><given-names>NL</given-names></name><name><surname>Rohde</surname><given-names>GG</given-names></name><name><surname>Beuken</surname><given-names>EV</given-names></name><name><surname>Grauls</surname><given-names>GE</given-names></name><name><surname>Bruggeman</surname><given-names>CA</given-names></name><name><surname>Stassen</surname><given-names>FR</given-names></name></person-group><article-title>Interferon-beta induces a long-lasting antiviral state in human respiratory epithelial cells</article-title><source>J Infect</source><year>2013</year><volume>66</volume><fpage>163</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2012.11.008</pub-id><?supplied-pmid 23201152?><pub-id pub-id-type="pmid">23201152</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aizaki</surname><given-names>H</given-names></name><name><surname>Saito</surname><given-names>S</given-names></name><name><surname>Ogino</surname><given-names>T</given-names></name><name><surname>Miyajima</surname><given-names>N</given-names></name><name><surname>Harada</surname><given-names>T</given-names></name><name><surname>Matsuura</surname><given-names>Y</given-names></name><name><surname>Miyamura</surname><given-names>T</given-names></name><name><surname>Kohase</surname><given-names>M</given-names></name></person-group><article-title>Suppression of interferon-induced antiviral activity in cells expressing hepatitis C virus proteins</article-title><source>J Interferon Cytokine Res</source><year>2000</year><volume>20</volume><fpage>1111</fpage><lpage>1120</lpage><pub-id pub-id-type="doi">10.1089/107999000750053780</pub-id><?supplied-pmid 11152578?><pub-id pub-id-type="pmid">11152578</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>P</given-names></name></person-group><article-title>Suppression of interferon-mediated antiviral immunity by hepatitis B virus: an overview of research progress</article-title><source>Scand J Immunol</source><year>2013</year><volume>78</volume><fpage>230</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1111/sji.12086</pub-id><?supplied-pmid 23790137?><pub-id pub-id-type="pmid">23790137</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Comar</surname><given-names>CE</given-names></name><name><surname>Goldstein</surname><given-names>SA</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Yount</surname><given-names>B</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name><name><surname>Weiss</surname><given-names>SR</given-names></name></person-group><article-title>Antagonism of dsRNA-induced innate immune pathways by NS4a and NS4b accessory proteins during MERS coronavirus infection</article-title><source>mBio</source><year>2019</year><volume>10</volume><fpage>e00319-19</fpage><pub-id pub-id-type="doi">10.1128/mBio.00319-19</pub-id><?supplied-pmid 30914508?><pub-id pub-id-type="pmid">30914508</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siu</surname><given-names>KL</given-names></name><name><surname>Chan</surname><given-names>CP</given-names></name><name><surname>Kok</surname><given-names>KH</given-names></name><name><surname>Chiu-Yat Woo</surname><given-names>P</given-names></name><name><surname>Jin</surname><given-names>DY</given-names></name></person-group><article-title>Suppression of innate antiviral response by severe acute respiratory syndrome coronavirus M protein is mediated through the first transmembrane domain</article-title><source>Cell Mol Immunol</source><year>2014</year><volume>11</volume><fpage>141</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1038/cmi.2013.61</pub-id><?supplied-pmid 24509444?><pub-id pub-id-type="pmid">24509444</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romeo</surname><given-names>G</given-names></name><name><surname>Affabris</surname><given-names>E</given-names></name><name><surname>Federico</surname><given-names>M</given-names></name><name><surname>Mechti</surname><given-names>N</given-names></name><name><surname>Coccia</surname><given-names>EM</given-names></name><name><surname>Jemma</surname><given-names>C</given-names></name><name><surname>Rossi</surname><given-names>GB</given-names></name></person-group><article-title>Establishment of the antiviral state in alpha, beta-interferon-resistant Friend cells treated with gamma-interferon. Induction of 67-kilodalton protein kinase activity in absence of detectable 2-5A synthetase</article-title><source>J Biol Chem</source><year>1985</year><volume>260</volume><fpage>3833</fpage><lpage>3838</lpage><?supplied-pmid 3919027?><pub-id pub-id-type="pmid">3919027</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>MJ</given-names></name></person-group><article-title>The role of interferon in the NK cell killing of virus-infected target cells</article-title><source>J Hyg</source><year>1982</year><volume>89</volume><fpage>347</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1017/S0022172400070881</pub-id><?supplied-pmid 6182244?><pub-id pub-id-type="pmid">6182244</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawelec</surname><given-names>G</given-names></name></person-group><article-title>Immunosenescence and cancer</article-title><source>Biogerontology</source><year>2017</year><volume>18</volume><fpage>717</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1007/s10522-017-9682-z</pub-id><?supplied-pmid 28220304?><pub-id pub-id-type="pmid">28220304</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanussi</surname><given-names>S</given-names></name><name><surname>Serraino</surname><given-names>D</given-names></name><name><surname>Dolcetti</surname><given-names>R</given-names></name><name><surname>Berretta</surname><given-names>M</given-names></name><name><surname>De Paoli</surname><given-names>P</given-names></name></person-group><article-title>Cancer, aging and immune reconstitution</article-title><source>Anticancer Agents Med Chem</source><year>2013</year><volume>13</volume><fpage>1310</fpage><lpage>1324</lpage><pub-id pub-id-type="doi">10.2174/18715206113136660348</pub-id><?supplied-pmid 24102279?><pub-id pub-id-type="pmid">24102279</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>HT</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Shin</surname><given-names>EC</given-names></name><name><surname>Lee</surname><given-names>WW</given-names></name></person-group><article-title>T cell senescence and cardiovascular diseases</article-title><source>Clin Exp Med</source><year>2016</year><volume>16</volume><fpage>257</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1007/s10238-015-0376-z</pub-id><?supplied-pmid 26188489?><pub-id pub-id-type="pmid">26188489</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costantini</surname><given-names>E</given-names></name><name><surname>D&#x02019;Angelo</surname><given-names>C</given-names></name><name><surname>Reale</surname><given-names>M</given-names></name></person-group><article-title>The role of immunosenescence in neurodegenerative diseases</article-title><source>Mediat Inflamm</source><year>2018</year><volume>2018</volume><fpage>6039171</fpage></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solana</surname><given-names>C</given-names></name><name><surname>Tarazona</surname><given-names>R</given-names></name><name><surname>Solana</surname><given-names>R</given-names></name></person-group><article-title>Immunosenescence of natural killer cells, inflammation, and alzheimer&#x02019;s disease</article-title><source>Int J Alzheimers Dis</source><year>2018</year><volume>2018</volume><fpage>3128758</fpage><?supplied-pmid 30515321?><pub-id pub-id-type="pmid">30515321</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whary</surname><given-names>MT</given-names></name><name><surname>Fox</surname><given-names>JG</given-names></name></person-group><article-title>Th1-mediated pathology in mouse models of human disease is ameliorated by concurrent Th2 responses to parasite antigens</article-title><source>Curr Top Med Chem</source><year>2004</year><volume>4</volume><fpage>531</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.2174/1568026043451276</pub-id><?supplied-pmid 14965304?><pub-id pub-id-type="pmid">14965304</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strober</surname><given-names>W</given-names></name><name><surname>Kelsall</surname><given-names>B</given-names></name><name><surname>Fuss</surname><given-names>I</given-names></name><name><surname>Marth</surname><given-names>T</given-names></name><name><surname>Ludviksson</surname><given-names>B</given-names></name><name><surname>Ehrhardt</surname><given-names>R</given-names></name><name><surname>Neurath</surname><given-names>M</given-names></name></person-group><article-title>Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation</article-title><source>Immunol Today</source><year>1997</year><volume>18</volume><fpage>61</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/S0167-5699(97)01000-1</pub-id><?supplied-pmid 9057354?><pub-id pub-id-type="pmid">9057354</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witkowski</surname><given-names>JM</given-names></name><name><surname>Bryl</surname><given-names>E</given-names></name><name><surname>Fulop</surname><given-names>T</given-names></name></person-group><article-title>Should we try to alleviate immunosenescence and inflammaging&#x02014;why, how and to what extent?</article-title><source>Curr Pharm Des</source><year>2019</year><volume>25</volume><fpage>4154</fpage><lpage>4162</lpage><pub-id pub-id-type="doi">10.2174/1381612825666191111153016</pub-id><?supplied-pmid 31713479?><pub-id pub-id-type="pmid">31713479</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>JS</given-names></name><name><surname>Chu</surname><given-names>CM</given-names></name><name><surname>Cheng</surname><given-names>VC</given-names></name><name><surname>Chan</surname><given-names>KS</given-names></name><name><surname>Hung</surname><given-names>IF</given-names></name><name><surname>Poon</surname><given-names>LL</given-names></name><name><surname>Law</surname><given-names>KI</given-names></name><name><surname>Tang</surname><given-names>BS</given-names></name><name><surname>Hon</surname><given-names>TY</given-names></name><name><surname>Chan</surname><given-names>CS</given-names></name><etal/></person-group><article-title>Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study</article-title><source>Lancet</source><year>2003</year><volume>361</volume><fpage>1767</fpage><lpage>1772</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(03)13412-5</pub-id><?supplied-pmid 12781535?><pub-id pub-id-type="pmid">12781535</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chien</surname><given-names>JY</given-names></name><name><surname>Hsueh</surname><given-names>PR</given-names></name><name><surname>Cheng</surname><given-names>WC</given-names></name><name><surname>Yu</surname><given-names>CJ</given-names></name><name><surname>Yang</surname><given-names>PC</given-names></name></person-group><article-title>Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome</article-title><source>Respirology</source><year>2006</year><volume>11</volume><fpage>715</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1843.2006.00942.x</pub-id><?supplied-pmid 17052299?><pub-id pub-id-type="pmid">17052299</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cameron</surname><given-names>MJ</given-names></name><name><surname>Ran</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Danesh</surname><given-names>A</given-names></name><name><surname>Bermejo-Martin</surname><given-names>JF</given-names></name><name><surname>Cameron</surname><given-names>CM</given-names></name><name><surname>Muller</surname><given-names>MP</given-names></name><name><surname>Gold</surname><given-names>WL</given-names></name><name><surname>Richardson</surname><given-names>SE</given-names></name><name><surname>Poutanen</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome</article-title><source>J Virol</source><year>2007</year><volume>81</volume><fpage>8692</fpage><lpage>8706</lpage><pub-id pub-id-type="doi">10.1128/JVI.00527-07</pub-id><?supplied-pmid 17537853?><pub-id pub-id-type="pmid">17537853</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oldstone</surname><given-names>MB</given-names></name><name><surname>Rosen</surname><given-names>H</given-names></name></person-group><article-title>Cytokine storm plays a direct role in the morbidity and mortality from influenza virus infection and is chemically treatable with a single sphingosine-1-phosphate agonist molecule</article-title><source>Curr Top Microbiol Immunol</source><year>2014</year><volume>378</volume><fpage>129</fpage><lpage>147</lpage><?supplied-pmid 24728596?><pub-id pub-id-type="pmid">24728596</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monneret</surname><given-names>G</given-names></name><name><surname>Gossez</surname><given-names>M</given-names></name><name><surname>Venet</surname><given-names>F</given-names></name></person-group><article-title>Sepsis and immunosenescence: closely associated in a vicious circle</article-title><source>Aging Clin Exp Res</source><year>2019</year><pub-id pub-id-type="doi">10.1007/s40520-019-01350-z</pub-id><?supplied-pmid 31522388?><pub-id pub-id-type="pmid">31522388</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reinhart</surname><given-names>K</given-names></name><name><surname>Daniels</surname><given-names>R</given-names></name><name><surname>Kissoon</surname><given-names>N</given-names></name><name><surname>Machado</surname><given-names>FR</given-names></name><name><surname>Schachter</surname><given-names>RD</given-names></name><name><surname>Finfer</surname><given-names>S</given-names></name></person-group><article-title>Recognizing sepsis as a global health priority&#x02014;a WHO resolution</article-title><source>N Engl J Med</source><year>2017</year><volume>377</volume><fpage>414</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1056/NEJMp1707170</pub-id><?supplied-pmid 28658587?><pub-id pub-id-type="pmid">28658587</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>TT</given-names></name><name><surname>Ewig</surname><given-names>S</given-names></name><name><surname>Rodloff</surname><given-names>AC</given-names></name><name><surname>Muller</surname><given-names>EE</given-names></name></person-group><article-title>Acute respiratory distress syndrome and pneumonia: a comprehensive review of clinical data</article-title><source>Clin Infect Dis</source><year>2006</year><volume>43</volume><fpage>748</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1086/506430</pub-id><?supplied-pmid 16912951?><pub-id pub-id-type="pmid">16912951</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joynt</surname><given-names>GM</given-names></name><name><surname>Yap</surname><given-names>HY</given-names></name></person-group><article-title>SARS in the intensive care unit</article-title><source>Curr Infect Dis Rep</source><year>2004</year><volume>6</volume><fpage>228</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1007/s11908-004-0013-6</pub-id><?supplied-pmid 15142487?><pub-id pub-id-type="pmid">15142487</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isobe</surname><given-names>KI</given-names></name><name><surname>Nishio</surname><given-names>N</given-names></name><name><surname>Hasegawa</surname><given-names>T</given-names></name></person-group><article-title>Immunological aspects of age-related diseases</article-title><source>World J Biol Chem</source><year>2017</year><volume>8</volume><fpage>129</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.4331/wjbc.v8.i2.129</pub-id><?supplied-pmid 28588756?><pub-id pub-id-type="pmid">28588756</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kale</surname><given-names>SS</given-names></name><name><surname>Yende</surname><given-names>S</given-names></name></person-group><article-title>Effects of aging on inflammation and hemostasis through the continuum of critical illness</article-title><source>Aging Dis</source><year>2011</year><volume>2</volume><fpage>501</fpage><lpage>511</lpage><?supplied-pmid 22396897?><pub-id pub-id-type="pmid">22396897</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alves</surname><given-names>AS</given-names></name><name><surname>Bueno</surname><given-names>V</given-names></name></person-group><article-title>Immunosenescence: participation of T lymphocytes and myeloid-derived suppressor cells in aging-related immune response changes</article-title><source>Einstein</source><year>2019</year><volume>17</volume><fpage>eRB4733</fpage><pub-id pub-id-type="doi">10.31744/einstein_journal/2019RB4733</pub-id><?supplied-pmid 31066797?><pub-id pub-id-type="pmid">31066797</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurez</surname><given-names>V</given-names></name><name><surname>Daniel</surname><given-names>BJ</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>AJ</given-names></name><name><surname>Ludwig</surname><given-names>SM</given-names></name><name><surname>Kious</surname><given-names>MJ</given-names></name><name><surname>Thibodeaux</surname><given-names>SR</given-names></name><name><surname>Pandeswara</surname><given-names>S</given-names></name><name><surname>Murthy</surname><given-names>K</given-names></name><name><surname>Livi</surname><given-names>CB</given-names></name><etal/></person-group><article-title>Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice</article-title><source>Cancer Res</source><year>2012</year><volume>72</volume><fpage>2089</fpage><lpage>2099</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-3019</pub-id><?supplied-pmid 22496463?><pub-id pub-id-type="pmid">22496463</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salminen</surname><given-names>A</given-names></name><name><surname>Kaarniranta</surname><given-names>K</given-names></name><name><surname>Kauppinen</surname><given-names>A</given-names></name></person-group><article-title>Immunosenescence: the potential role of myeloid-derived suppressor cells (MDSC) in age-related immune deficiency</article-title><source>Cell Mol Life Sci</source><year>2019</year><volume>76</volume><fpage>1901</fpage><lpage>1918</lpage><pub-id pub-id-type="doi">10.1007/s00018-019-03048-x</pub-id><?supplied-pmid 30788516?><pub-id pub-id-type="pmid">30788516</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venet</surname><given-names>F</given-names></name><name><surname>Demaret</surname><given-names>J</given-names></name><name><surname>Gossez</surname><given-names>M</given-names></name><name><surname>Monneret</surname><given-names>G</given-names></name></person-group><article-title>Myeloid cells in sepsis-acquired immunodeficiency</article-title><source>Ann N Y Acad Sci</source><year>2020</year><pub-id pub-id-type="doi">10.1111/nyas.14333</pub-id><?supplied-pmid 32202669?><pub-id pub-id-type="pmid">32202669</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Netherby</surname><given-names>CS</given-names></name><name><surname>Abrams</surname><given-names>SI</given-names></name></person-group><article-title>Mechanisms overseeing myeloid-derived suppressor cell production in neoplastic disease</article-title><source>Cancer Immunol Immunother</source><year>2017</year><volume>66</volume><fpage>989</fpage><lpage>996</lpage><pub-id pub-id-type="doi">10.1007/s00262-017-1963-5</pub-id><?supplied-pmid 28224211?><pub-id pub-id-type="pmid">28224211</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonda</surname><given-names>K</given-names></name><name><surname>Shibata</surname><given-names>M</given-names></name><name><surname>Ohtake</surname><given-names>T</given-names></name><name><surname>Matsumoto</surname><given-names>Y</given-names></name><name><surname>Tachibana</surname><given-names>K</given-names></name><name><surname>Abe</surname><given-names>N</given-names></name><name><surname>Ohto</surname><given-names>H</given-names></name><name><surname>Sakurai</surname><given-names>K</given-names></name><name><surname>Takenoshita</surname><given-names>S</given-names></name></person-group><article-title>Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer</article-title><source>Oncol Lett</source><year>2017</year><volume>14</volume><fpage>1766</fpage><lpage>1774</lpage><pub-id pub-id-type="doi">10.3892/ol.2017.6305</pub-id><?supplied-pmid 28789407?><pub-id pub-id-type="pmid">28789407</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nam</surname><given-names>S</given-names></name><name><surname>Kang</surname><given-names>K</given-names></name><name><surname>Cha</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Lee</surname><given-names>HG</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>MS</given-names></name><name><surname>Lim</surname><given-names>JS</given-names></name></person-group><article-title>Interferon regulatory factor 4 (IRF4) controls myeloid-derived suppressor cell (MDSC) differentiation and function</article-title><source>J Leukoc Biol</source><year>2016</year><volume>100</volume><fpage>1273</fpage><lpage>1284</lpage><pub-id pub-id-type="doi">10.1189/jlb.1A0215-068RR</pub-id><?supplied-pmid 27601624?><pub-id pub-id-type="pmid">27601624</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medina-Echeverz</surname><given-names>J</given-names></name><name><surname>Haile</surname><given-names>LA</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Gamrekelashvili</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Metais</surname><given-names>JY</given-names></name><name><surname>Dunbar</surname><given-names>CE</given-names></name><name><surname>Kapoor</surname><given-names>V</given-names></name><name><surname>Manns</surname><given-names>MP</given-names></name><name><surname>Korangy</surname><given-names>F</given-names></name><name><surname>Greten</surname><given-names>TF</given-names></name></person-group><article-title>IFN-gamma regulates survival and function of tumor-induced CD11b+ Gr-1high myeloid derived suppressor cells by modulating the anti-apoptotic molecule Bcl2a1</article-title><source>Eur J Immunol</source><year>2014</year><volume>44</volume><fpage>2457</fpage><lpage>2467</lpage><pub-id pub-id-type="doi">10.1002/eji.201444497</pub-id><?supplied-pmid 24810636?><pub-id pub-id-type="pmid">24810636</pub-id></element-citation></ref></ref-list></back></article>